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ABSTRACT 
 
Hereditary  haemochromatosis  is  an  autosomal  recessive  disorder  of  iron 
metabolism,  characterised  by  increased  iron  absorption  and  progressive  iron 
accumulation particularly  in  the liver.  It  has  been shown that hepatocytes can 
acquire iron in two forms; transferrin-bound iron (TBI) and non-transferrin-bound 
iron  (NTBI)
1.  Known  transporters  of  NTBI  into  the  cell  include  DMT1  and 
ZIP14, and FPN is the only transporter known to export iron.  
 
The  aims  of  this  study  were  to  characterize  the  zinc  transporter,  ZnT-1  and 
determine whether it is involved in iron transport, specifically as an exporter. 
 
There was a decrease in mRNA expression of the short untranslated isoform of 
ZnT-1 in double mutant (Hfe -/- and TfR2 Y245X) mouse liver, a trend also seen 
in TfR1 and Hamp. The long untranslated isoform, however, was significantly 
higher in the iron-deficient mice as was expression of TfR1 and Ferroportin. Iron 
and zinc efflux was measured in cells over-expressing ZnT-1 and control cells. 
There was no difference between over-expressed and control cells in iron efflux. 
However, at 60 min, over-expressed cells had significantly more zinc efflux than 
control cells. More zinc than iron was released from the cell. 
 
The results of this study do not support the hypotheses that (i) ZnT-1 reduces 
intracellular cytoplasmic iron concentration by promoting efflux and 
2 ZnT-1 is 
down-regulated in iron-loaded cells.   15 
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1.1 The Importance of Iron 
Iron is vital for most living organisms as it is essential for numerous metabolic 
processes  including  oxygen  transport,  DNA  synthesis,  energy  production  and 
electron  transfer
3.  Additionally  it  is  a  co-factor  in  proteins  including  those 
involved in crucial enzymatic processes
4. Iron has the capacity to cycle between 
ferric (Fe
3+) and ferrous (Fe
2+) forms through the donation or acceptance of an 
electron
5: 
Fe
3+ + O2
-         Fe
2+ + O2 
This  capability  makes  iron  highly  important  in  biological  systems
6.  However, 
under physiological conditions, ferrous iron is almost insoluble and potentially 
toxic due to the generation of highly reactive free radicals such as O2 and OH
-, 
resulting  in  tissue  damage
5.  Therefore,  iron‟s  availability  must  be  regulated 
carefully  to  maintain  homeostasis  and  prevent  iron  disorders  such  as  iron 
deficiency and iron overload
4. 
 
1.2 Iron disorders 
Since the human body has not evolved a mechanism to clear excess iron, disorders 
of iron balance, such as iron overload and iron deficiency, are common diseases in 
humans
7. 
 
Iron deficiency is the most common known form of nutritional deficiency. Its 
causes include inadequate intake, blood loss and interference with absorption due 
to  substances  in  the  diet  or  drugs
8.  Conversely,  iron  overload  disorders  are 
diseases caused by the accumulation of iron in the body. Primary iron overload is 
generally due to a genetic factor resulting in a disease such as haemochromatosis,   17 
and secondary iron overload is an acquired condition due to excessive absorption 
of dietary iron, repeated blood transfusions and other chronic liver disease such as 
cirrhosis and hepatitis C
9. However, given the focus of this study, discussion will 
be limited to haemochromatosis. 
 
1.2.1 Haemochromatosis 
Hereditary haemochromatosis (HH) is a disease that causes the body to absorb too 
much iron from the diet leading to the accumulation of iron in organs including 
the liver, heart, pancreas and gonads
5. Body iron stores accumulate slowly with 
the majority of patients presenting with symptoms at the age of 40 – 60 years
4. 
The most common, HH type 1 is transmitted in an autosomal recessive fashion 
and represents more than 90% of iron-overload syndromes of genetic origin
10. 
Furthermore,  it  is  the  most  common  genetic  disorder  among  Caucasians  of 
northern European descent, with a prevalence of 1:190 in Australia
11. HH type 1 
occurs as a result of a mutation in the HFE gene. First identified in humans in 
1996, the HFE gene is located on the short arm of chromosome 6. HFE is a 343 
amino  acid  protein  with  homology  to  the  major  histocompatibility  complex 
(MHC) class I molecules. In HH type 1, a C282Y mutation to the  HFE gene 
causes altered folding of the protein preventing its transport to the cell surface, 
thereby  disabling  its  ability  to  down-regulate  cellular  iron  uptake
12.  The  less 
common H63D mutation is not associated with the same degree of iron overload 
as the C282Y mutation
13. 
 
Juvenile  or  HH  type  2  is  a  rare  autosomal  recessive  disorder  which  causes 
progressive elevated iron absorption with clinical symptoms appearing usually at   18 
the age of 20 – 30 years. There are two genetic forms of HH type 2; type 2A, the 
most common form is caused by mutations in the hemojuvelin gene (HJV) and 
type 2B is caused by mutations in the hepcidin gene (HAMP)
9. 
 
HH  type  3  is  a  rare  autosomal  recessive  disorder  resulting  in  elevated  iron 
absorption  due  to  mutations  in  the  transferrin  receptor  2  gene  (TfR2).  First 
described in four families as a homozygous nonsense mutation (Y250X)
14, several 
mutations have since been characterised. HH type 3 is a more severe form of HH 
and clinical and pathological characteristics resemble those of classic HFE-related 
HH
15. 
 
HH type 4, also known as ferroportin disease type B
16 or ferroportin-associated 
iron overload
17, is an autosomal dominant disorder which causes elevated iron 
absorption due to a mutation involving three sequential bases in exon five
17 in the 
ferroportin 1 gene (FPN1). Although there is a severe iron load, the phenotype 
appears to be mild and liver disease is limited to fibrosis, primarily sinusoidal
17. 
 
1.2.2 Hfe Gene Knockout (KO) Mouse Model of HH Type 1 
The Hfe KO mouse model was created in 1998 by Zhou et al. by homologous 
recombination  resulting  in  a  disrupted  Hfe  gene.  The  Hfe  KO  mice  are 
homozygous for the null allele and exhibit abnormally high transferrin saturation 
and  excessive  accumulation  of  iron  in  the  liver,  predominantly  in  the 
hepatocytes
18. 
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1.2.3 TfR2 Mutant Mouse Model of HH Type 3 
The TfR2 mouse model was developed in 2002 by introducing a premature stop 
codon  (Y245X)  in  the  TfR2  coding  sequence  by  targeted  mutagenesis. 
Orthologous to the Y250X mutation identified in patients with HH type 3, the 
homozygous  TfR2 (Y245X) mutant  mice show  profound abnormalities  in  iron 
homeostasis and demonstrate elevated transferrin saturations
19. 
 
1.2.4 Hfe -/-/TfR2 Y245X Double Mutant Mouse Model 
The Hfe -/-/TfR2 Y245X mouse model was recently developed by breeding Hfe 
and  TfR2  mice  to  homogeneity  on  a  AKR  background  to  generate  mutants 
homozygous  for  each  gene  disruption.  The  double  mutants  have  more  severe 
loading compared to mice carrying the Hfe or TfR2 mutation alone resulting in a 
more severe early onset with a phenotype similar to HH type 2
20; 21; 22. 
 
1.3 Distribution of Iron in the Body 
Body iron stores are approximately 45 to 55 mg per kilogram of body weight in 
an adult male and approximately 35 to 45 mg per kilogram of body weight in a 
premenopausal  woman
6.  However,  after  menopause  and  the  cessation  of 
menstruation, iron stores increase
23. Body iron stores are maintained at a steady 
state because dietary iron intake is balanced by normal, gradual iron loss
4. 
 
Iron homeostasis is primarily maintained by regulating the absorption of iron from 
the diet as well as its distribution within the body
24. Dietary iron is absorbed in the 
duodenum by enterocytes and circulates in the plasma bound to transferrin and is   20 
utilised by tissues throughout the body. Circulating red blood cells comprise the 
largest iron storage pool, and when senescent red blood cells are engulfed by 
reticuloendothelial macrophages, iron is made available for redistribution to other 
tissues  such  as  the  liver  which  is  the  main  site  of  iron  storage.  Most  of  the 
circulating iron is used by the bone marrow to generate haemoglobin for red blood 
cells, while around 10 – 15% is used by muscle fibres to generate myoglobin. 
About 1 – 2 mg of iron is lost each day via, cell shedding from the skin,  sloughed 
mucosal cells, menstruation or other blood loss (Figure 1.1)
6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Distribution and content of iron in the adult body. Reproduced 
from Andrews
6.   21 
1.4 Intestinal Iron Absorption 
Dietary iron absorption takes place in the duodenum across the apical membrane 
of mature enterocytes. Haem iron is transported into the cell by a carrier yet to be 
identified
25.  Non-haem  iron  is  imported  into  the  cell  by  the  divalent  metal 
transporter protein (DMT1)
26. After enzymatic  reduction from  Fe
3+ to Fe
2+ by 
duodenal cytochrome b (Dcytb), and uptake by DMT1, non-haem iron can either 
be stored within the cell as ferritin, or transferred across the basolateral membrane 
into  the  blood  by  ferroportin,  also  known  as  iron  regulated  transporter  1 
(IREG1)
25. Iron release is facilitated by hephaestin which assists ferroportin by 
oxidizing  iron  for  loading  on  to  transferrin  in  the  plasma
27  (Figure  1.2).  Iron 
absorption  is  also  regulated  by  hepcidin,  the  hepatic  iron  regulatory  hormone 
which binds to ferroportin molecules on the surface of duodenal enterocytes and 
mediates its degradation, thus inhibiting the export of iron from the enterocytes
16. 
 
Haem iron absorption is thought to be mediated by a carrier which is yet to be 
identified
25. Upon entering the cell, haem iron is degraded by haem oxygenase 
and the released ferrous iron appears to join the same intracellular pathway as 
non-haem iron
26 (Figure 1.2). 
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Figure 1.2: Absorption of iron in the gut. Iron absorption occurs across the 
apical membrane into enterocytes and is either stored in ferritin or transferred 
across the basolateral membrane into the blood. Reproduced from Trinder et al.
28. 
 
1.5 Cellular Iron Uptake and Storage 
The  majority  of  iron  is  transported  in  the  plasma  bound  to  transferrin  which 
maintains  iron  in  a  soluble  form  at  near  neutral  pH  and  prevents  free  radical 
formation
3. Each transferrin molecule binds two atoms of ferric iron
29 and allows 
it  to  be  transported  between  the  sites  of  absorption,  storage  and  use  by  body 
organs
3.  Transferrin-bound  iron  (TBI)  is  mediated  by  cell  surface  receptors 
transferrin receptor 1 (TFR1) and transferrin receptor 2 (TFR2)
30. 
 
Iron  also  circulates  in  a  chelatable,  low  molecular  weight  form  and  the  main 
species is ferric citrate. Known transporters of non-transferrin-bound iron (NTBI) 
include DMT1 and zinc-regulated transporter and iron-regulated transporter-like   23 
protein 14 (ZIP14)
31, which first discovered to transport zinc, has recently been 
reported to transport iron in an in vitro model
32. 
 
1.6 Hepatic Iron Transport 
The  liver  is  the  main  site  of  iron  storage  and  iron  is  stored  as  ferritin  or 
haemosiderin
29.  Figure  1.3  shows  how  under  conditions  of  normal  iron 
homeostasis, transferrin-bound iron binds to TFR1 or TFR2 and is taken up by 
receptor-mediated endocytosis. The endosome is acidified and Fe
3+ is reduced by 
six-transmembrane epithelial antigen of prostate protein 3 (STEAP3). The iron is 
released and transported out of the endosome via DMT1 and apotransferrin (iron-
free)  is  exocytosed.  Uptake  of  NTBI  occurs  via  reduction  on  the  hepatocyte 
surface by a ferrireductase and transported by DMT1 or ZIP14. Iron within the 
transit pool is stored as ferritin or released from the cell by ferroportin (FPN) 
where it is oxidized by caeruloplasmin and binds to apotransferrin. 
Figure 1.3: Iron Transport in the Hepatocyte. Iron is transported into the cell 
as TBI or NTBI where it is stored as ferritin. Iron is released by FPN where it 
binds to apotransferrin. Adapted from Graham et al.
31.   24 
The  cellular  uptake  of  transferrin  bound  iron  is  controlled  by  regulating  the 
expression  of  TFR1  through  iron  response  elements  (IRE)  that  regulate  the 
transcription of transferrin receptors
33. IREs are located in the untranslated region 
of mRNAs and are responsive to iron
34. When iron levels are low, iron response 
proteins (IRP) bind to IREs in the 3‟ untranslated region of TFR1 mRNA which 
stabilizes the mRNA and prevents degradation thus increasing its translation
35. 
Conversely, when iron levels are high, binding of IRPs to the IRE is decreased 
and TfR1 is destabilized resulting in subsequent decreases in protein synthesis and 
iron transport
36. 
 
Release of iron from the cell is regulated by the liver-produced hormone hepcidin. 
High  iron  concentrations  lead  to  the  secretion  of  hepcidin  which  binds  to 
ferroportin and induces its internalisation and degradation thus preventing iron 
efflux
37. 
 
While it has been established that TBI is  released from the cell via FPN, the 
mechanism for NTBI export is yet to be explained. It is now known that DMT1 
and  ZIP14  are  capable  of  transporting  more  than  one  metal
31,  therefore  it  is 
reasonable to suggest a zinc transporter as a possible candidate for the export of 
iron.  Zinc  Transporter  1  (ZNT-1)  is  located  on  the  plasma  membrane  and 
transports zinc out of the cell in the same way that ferroportin transports iron so, 
could ZnT-1 be involved in iron homeostasis? 
 
 
   25 
1.7 Introduction to Zinc 
Zinc  is  a  metallic  trace  element  that  is  essential  for  human  health  and 
development. The adult human body contains about 2 to 3 grams of zinc
38 which 
is distributed in all body tissues, with 85% of the whole body zinc in muscle and 
bone, 11% in the skin and the liver and the remaining in all the other tissues
39. 
Zinc has been known to be an essential trace element for more than a century; 
however, it was not until 1940 when Keilin and Mann discovered zinc in carbonic 
anhydrase that a specific biological role was established
40. It is estimated that at 
least 10% of the hundreds of thousands of proteins in the human body contain 
zinc prosthetic groups
41 and over three hundred of these proteins are involved in 
crucial  enzymatic  processes  including  representatives  from  all  six  major 
functional enzyme classes
42. In addition, zinc ions have now been recognized as 
important  signalling  molecules  which  activate  intracellular  pathways  via  an 
extracellular  zinc  sensing  receptor  (ZnR)
43.  These  pathways  regulate  key  cell 
functions  such  as  cell  proliferation  and  survival
44,  ion  transport
45  as  well  as 
hormone  secretion
43.  Consequently,  mechanisms  exist  to  ensure  that  adequate 
intracellular zinc concentrations are maintained in order to support these essential 
roles  regardless  of  whether  extracellular  or  dietary  levels  are  minimal  or 
excessive
46. 
 
1.8 Zinc Homeostasis 
Homeostasis is maintained through a regulated rate of intestinal uptake, faecal and 
to a lesser extent urinary excretion, renal reabsorption and distribution to cells
47. 
Zinc is absorbed by the small intestine
48 and released into the portal circulation 
where, after binding with albumin and α2-macroglobulin
49, it is taken up across   26 
the plasma membrane into the cytosol where only a small amount, well below 
nanomolar levels, of free zinc remain
47. The balance is thought to be available for 
three  additional  intracellular  pools  (Figure  1.4)
47.  Zinc  binds  tightly  to 
metalloproteins as a structural component or a cofactor
42. In addition, low affinity 
metallothioneins bind zinc; this is believed to provide an important labile pool 
thought  to  be  a  reservoir  and  buffer  of  cytosolic  zinc
50.  Furthermore,  zinc  is 
compartmentalized  into  intracellular  organelles  such  as  mitochondria,  the 
endoplasmic  reticulum  (ER),  and  the  Golgi  apparatus,  as  well  as  specialized 
organelles such as synaptic vesicles and secretory granules to be used by zinc-
dependent proteins
47. In addition, zinc is transported into an endosomal/lysosomal 
compartment thought to be facilitated by ZnT-2
51. Gaither and Eide hypothesised 
the binding of zinc to metallothionein proteins along with sequestration within 
organelles  or  efflux  across  the  plasma  membrane  to  serve  as  a  detoxification 
mechanism
46. 
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Figure 1.4: Zinc Transporters. The transport of zinc into or out of cytoplasm is 
directed  by  two  zinc  transporter  families,  the  ZIP  family  are  involved  in  the 
uptake of zinc and ZnT family are involved in zinc efflux. Zinc in mammalian 
cells  exists  in  four  distinct  pools;  (A)  Zinc  in  cytoplasm  is  tightly  bound  to 
metalloproteins as a structural component or as a cofactor or (B) loosely bound to 
metalloproteins  to  reserve  zinc.  (C)  Zinc  is  compartmentalized  in  intracellular 
organelles. (D) The free zinc concentration in the cytosol is estimated to be well 
below a nanomolar level. Reproduced from Kambe et al.
47. 
 
 
 
1.9 Zinc Transporters 
Central to the movement of zinc into or out of the cytoplasm are the zinc transport 
proteins. To date, known mammalian zinc transporters come mainly from two 
families, ZnT/CDF and  ZIP
52, both of which are part of the solute carrier (SLC) 
group of transport proteins and, hence, are also referred to as SLC30 and SLC39, 
respectively
53. By convention, members within an individual SLC family have 
greater  than  20%  sequence  homology  to  each  other;  however,  the  homology 
between SLC families is very low to non-existent
53. Therefore, the criteria for 
inclusion of a family into the SLC group are functional
53. ZnTs and ZIPs appear 
to have opposing roles; ZnTs reduce intracellular cytoplasmic zinc by promoting 
zinc efflux or compartmentalization, while ZIPs are involved in the uptake of zinc 
ZIP   ZNT 
Metallothionein   28 
from  outside  the  cell  into  the  cytoplasm  as  well  as  transporting  it  from 
intracellular  organelles  into  the  cytoplasm
52  (Figure  1.4).  Since  this  project 
involves  the  characterization  of  ZnT-1,  discussion  will  be  limited  to  this 
transporter. 
 
1.9.1 Zinc Transporter 1 
ZnT-1  was  the  first  zinc  transporter  to  be  discovered,  it  was  mapped  to 
chromosome one in humans and, with two exons, it has the simplest structure of 
the ZnT family
54. cDNA predicts a 507 amino acid protein with six predicted 
transmembrane  domains
46  and  cytoplasmic  amino  and  carboxy  termini
55.  In 
addition, the ZnT proteins have histidine rich motifs usually in the cytoplasmic 
loop between transmembrane domain IV and V, which is thought to act as a metal 
binding domain
56 (Figure 1.5). Furthermore, alterations within this loop affect its 
metal specificity, suggesting it is also involved in metal recognition
47.   
 
 
 
 
 
 
 
 
Figure 1.5: Typical structure of a ZnT zinc transporter. A six transmembrane 
domain integral protein with cytosolic C and N termini, as well a histidine-rich 
loop. Reproduced from Harris
56. 
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Palmiter  and  Findley  reported  zinc  efflux  and  a  reduced  concentration  of 
intracellular zinc in cells over-expressing ZnT-1, furthermore imunocytochemistry 
revealed localisation to the plasma membrane suggesting that ZnT-1 was involved 
in transporting zinc out of the cell
57. To date it is the only member of the SLC30 
family whose prime location is on the plasma membrane
58.  
 
Although ZnT-1 mRNA is ubiquitously expressed, its abundance differs among 
tissues
59,  however  it  is  particularly  abundant  in  intestine,  liver
60,  kidney, 
placenta
47 and the brain
61. McMahon and Cousins, reported two transcript sizes 
for  ZnT-1  mRNA  and  suggest  that  this  is  a  result  of  mRNA  processing
60. 
Expression  is  regulated  by  dietary  zinc
60  which  is  believed  to  occur  by  a 
mechanism  involving  the  metal  response  element-binding  transcription  factor 
(MTF)-1 which binds actively to two metal-response element sequences on the 
ZnT-1 promoter
62. Protein expression has been reported to be highly expressed in 
the  brain
61,  epithelium  of  the  esophageus,  duodenum  of  the  small  intestine, 
caecum of the large intestine
63, and the liver
60. However, Western blot analysis of 
intestine and liver tissues detects two different sized proteins suggesting that the 
protein  is  subject  to  post-translational  modifications  in  a  tissue-dependent 
manner
47. 
 
1.10 Microarray Analysis of ZnT-1 
Recently, Microarray analysis was performed to determine ZnT-1 expression in 
liver  from  wild  type,  iron-loaded  and  TfR2  Y245X  mutant  mouse  models
64. 
Probes  targeted  two  areas  of  the  ZnT-1  mRNA,  designated  short  untranslated 
isoform (SUI) and long untranslated isoform (LUI), for the 5‟ untranslated region   30 
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and  3‟  untranslated  region  of  the  mRNA  respectively.  The  results  showed  a 
decreased level of expression of the ZnT-1 SUI in iron-loaded and TfR2 Y245X 
mice compared to wild type mice (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Microarray of ZnT-1 LUI and SUI. Results are expressed as mean ± 
SD. There was a decreased level of expression of the ZnT-1 SUI in iron-loaded 
and TfR2 Y245X mice compared to wild type mice. 
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1.11 Statement of Aims 
ZNT-1 is located on the plasma membrane and is involved in zinc efflux. It has 
now been established that DMT1 and ZIP14 are capable of transporting more than 
one metal, therefore it is reasonable to suggest a zinc transporter as a possible 
candidate for the export of iron. This project aims to determine whether ZnT-1 is 
involved in iron transport. 
 
1.12 Hypotheses 
1)   ZnT-1  reduces  intracellular  cytoplasmic  iron  concentration  by  promoting 
  efflux. 
 
2)    ZnT-1 is down regulated in iron-loaded cells and contributes to hepatic iron 
  loading characteristic of haemochromatosis. 
 
1.13 Research Plan 
Aim 1:  To  analyse  liver  ZnT-1  expression  in  wild-type  mice  fed  either  a 
  control, iron-deficient or iron-loaded diet, Hfe knockout, TfR2 mutant 
  and Hfe x TfR2 double mutant mouse models of HH and in hepatic 
  cells over-expressing the ZnT-1  gene. 
RNA was extracted from mouse liver and reverse transcribed to generate cDNA to 
be used in RT-PCR analysis. RT-PCR was used to amplify a region of the gene 
that quantifies the level of ZnT-1 transcript as well as Fpn, TfR1 and Hamp. In 
addition, RNA was extracted and mRNA expression of ZnT-1, Fpn, Dmt1 and 
Zip14 was analysed by RT-PCR.   32 
Aim 2:  To  clone  ZnT-1  into  a  Gateway
®  vector  with  a  Green  Fluorescent 
  Protein (GFP) N-terminal tag.  
The ZnT-1 coding sequence of the gene was amplified by PCR using primers 
designed with attB sites to facilitate cloning into a Gateway
® vector to produce an 
entry clone which was subjected to a number of screening processes including, 
PCR,  agarose  gel  electrophoresis  and  sequencing  before  being  cloned  into  a 
Gateway
® destination vector to generate an expression clone.  
 
Aim 3:  To determine the cellular localisation of ZnT-1  
AML12  mouse  hepatocytes  were  transfected  with  the  expression  clone  to  
produce  a  GFP  ZnT-1  fusion  protein  which  was  visualised  by  fluorescence 
microscopy to determine its cellular location. In addition protein was extracted 
from the cells and Western immunoblotting was performed to confirm protein 
expression. 
 
Aim 4:  To measure iron and zinc uptake and release in cells over expressing 
  ZnT-1. 
AML12 cells over expressing ZnT-1 and non-transfected cells were loaded with 
radio-labelled zinc and iron and the amount of zinc and iron taken up and released 
by the cells was measured.  
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2.1 MATERIALS AND EQUIPMENT 
 
 
 
2.1.1 RNA Extraction, DNase Treatment and Quantification 
Item  Supplier 
Biological Safety Cabinet (Gelman BH-2000  Gelman Sciences, Australia 
Cabinet Class II) 
 
Block Heater (Thermolyne)  Laboratory Supply, Australia 
 
BCP Phase Separation Reagent  Sigma-Aldrich, USA 
(1-Bromo-3-chloropropane) 
 
rDNase 1 (2U/µL)  Ambion Inc, USA 
 
DNase 1 Buffer (10x)  Ambion Inc, USA 
 
DNase Inactivation Reagent  Ambion Inc, USA 
 
Absolute Ethanol (C2H5OH)  BDH Merck Pty Ltd, Australia 
 
Homogeniser (Ultra-Turrax T25)  John Morris Scientific, Australia 
 
Isopropanol (C3H8O)  BDH Merck Pty. Ltd., Australia 
 
Spectrophotometer (DU 640)  Beckman Coulter, USA 
 
Tri-Reagent (RNA Isolation Reagent)  Ambion Inc, USA 
 
 
 
2.1.2 Reverse Transcription, RT-PCR and PCR 
Item  Supplier 
 
Dimethyl Sulphoxide (DMSO)  Sigma-Aldrich, USA 
 
Dithiothreitol (DTT) 0.1 M  Invitrogen,  Australia 
 
DNA Polymerase: HiFi Platinum Taq,  Invitrogen, Australia 
Pfx50, Pfu and Platinum Taq (5 U/μL)   
 
dNTPs (100 mM)  Fisher Biotec, Australia 
 
Ethylenediaminetetraaceticacid (EDTA)  Merck, Germany   35 
First Strand RT Buffer (5x)  Invitrogen, Australia 
 
Magnesium Chloride (MgCl2) (50 mM)  Invitrogen, Australia 
 
Magnesium Sulphate (MgSO4) (50 mM)  Invitrogen, Australia 
 
Oligo dT Primer (0.5 mg/mL)  Promega Corp, USA 
 
PCR Buffer: HiFi Platinum Taq,  Invitrogen,  Australia 
Pfx50, Pfu and Platinum Taq (10x)   
 
PCR Enhancer Solution (10x)  Invitrogen, Australia 
 
PCR Enhancer, Q Solution (5x)  QIAGEN, Australia 
 
Primers  Invitrogen, Australia 
 
Real-Time Cycler (Corbett Research  Fisher Biotec, Australia 
RG 2000 &  3000) 
 
Reverse Transcriptase, Superscript III   Invitrogen, Australia 
(200 U/µL) 
 
RNasin RNase Inhibitor (40 U/µL)  Promega Corp, USA 
 
SYBR Green (10x)  Invitrogen, Australia 
 
Thermal Controller (PTC-100TM)   Gene Works Pty Ltd, Australia 
 
Tris  BDH AnalaR, Australia 
 
 
 
2.1.3 Agarose Gel Electrophoresis 
Item  Supplier 
 
Agarose (Analytical Grade)  Promega Corp, USA 
 
Ethylenediaminetetraaceticacid (EDTA)  Merck, Germany 
 
Ethidium Bromide (10 mg/mL)  Promega Corp, USA 
 
Gel Tank  Bio-Rad Laboratories, USA/Fisher 
Biotec, Australia 
 
Glacial Acetic Acid (CH3COOH)  Merck, Germany 
 
6x Loading Dye (Blue/Orange)  Promega Corp, USA 
   36 
1 Kb Plus Molecular Weight Marker   GIBCO
™ Invitrogen, Australia 
 
Power Pac 300  Bio-Rad laboratories, USA 
 
Tris  BDH AnalaR, Australia 
 
VersaDoc Imaging System 3000  Bio-Rad Laboratories, USA 
 
 
 
2.1.4 Cloning 
Item  Supplier 
Ampicillin  Sigma-Aldrich, USA 
Bacto Agar  Bacto Laboratories, Australia 
 
Bacto Tryptone  BD  Beckton,  Dickinson  &  Co, 
USA 
 
5-bromo-4-chloro-3-indoyl-ß-D- Galactoside  Fisher Biotec, Australia 
N, N-dimmethylformamide (X-gal) 
 
Centrifuge (Beckman J2-MI and JA17 rotor)  Beckman Instruments, Australia 
 
ChargeSwitch
®-Pro PCR Clean-up Kit  Invitrogen, Australia  
 
Cryotubes (2 mL)  Sarstedt AG & Co, USA 
 
Disposable Inoculating Loops (1 µL)  Copan, Italy 
 
Dimethylformamide (DMF)   Sigma-Aldrich, USA 
 
E. coli DH5-α  Invitrogen, Australia 
 
FastPlasmid
™ Mini Kit  Eppendorf, Australia 
 
Gateway® Technology PCR Cloning System  Invitrogen, Australia 
 
Glucose  Sigma, USA 
 
Incubator Shaker (Innova 4000)  John Morris Scientific, Australia 
 
Isopropyl ß-D-1 thiogalactopyranoside  Sigma-Aldrich, USA 
(IPTG) 
 
Kanamycin  Sigma-Aldrich, USA 
 
Potassium chloride (KCl)  BDH AnalaR, Australia   37 
Magnesium chloride hexahydrate  BDH AnalaR, Australia 
(MgCl2.6H2O) 
 
Magnesium sulphate heptahydrate  BDH GPR
™, UK 
(MgSO4.7H2O) 
 
Sodium chloride (NaCl)  Merck, Germany 
 
Petri Dish (90 x 14 Full Plate)  Sarstedt, Australia 
 
pGEM®-T Easy Vector System  Promega Corp, USA 
 
PureLink
™ PCR Purification Kit  Invitrogen, Australia 
 
PureLink™ HiPure Plasmid Filter   Invitrogen, Australia 
Purification Kit  
 
QIAquick
® Gel Extraction Kit  QIAGEN, Australia 
 
QIAGEN Plasmid Maxi Kit    QIAGEN, Australia 
 
QIAprep
® Spin Miniprep Kit   QIAGEN, Australia 
 
Spectrophotometer (DU 640)  Beckman Coulter, USA 
 
Yeast Extract  Oxoid, Australia 
 
 
 
2.1.5 Cell Culture & Fluorescence Microscopy 
Item  Supplier 
 
Acetone ((CH3)2CO)  Sigma-Aldrich, USA 
 
Biological Safety Cabinet (Gelman BH-2000  Gelman Sciences, Australia 
Cabinet Class II) 
 
Culture Plates (MULTIWELL
TM 6-Well)  BD Falcon, USA 
 
Culture Plates (MULTIWELL
TM 12-Well)  BD Falcon, USA 
 
Culture Slide (4 Chamber Tissue Culture  BD Falcon, USA 
treated Glass Slide) 
 
Dexamethasone   Sigma, USA 
 
Dulbecco‟s modified eagle medium   GIBCO™ Invitrogen, Australia 
nutrient mix (DMEM-F12) 
   38 
Foetal Bovine Serum (FBS)  GIBCO™ Invitrogen, Australia 
 
Gentamicin (40 mg/mL)  Pfizer, Australia 
 
Haemocytometer (Brand)  Hirschmann EM Techcolor  
 
Immersion Oil  Nikon, Japan 
 
Incubator (CO2 Forma Series II Water  Forma Scientific Inc, USA 
Jacketed HEPA Class 100) 
 
Insulin-Transferrin-Selenium (ITS)  BD Biosciences, USA 
Supplement Premix (100x)   
 
L-glutamine  GIBCO™ Invitrogen, Australia 
 
Methanol (CH3OH)  BDH Laboratory Supplies, UK 
 
Sodium bicarbonate (NaHCO3)  BDH AnalaR, Australia 
 
Microscope (Eclipse TE2000-U with   Nikon, Japan 
DS Camera DS-L1) 
 
Microscope (Olympus CK2)  Olympus, Japan 
 
Needle (23 G Precision Glide)  Becton Dickson, Singapore 
 
Phosphate Buffered Saline powder (PBS)  Thermo Electron, Australia 
 
Prolong
® Gold antifade reagent with DAPI  Invitrogen, Australia 
 
Syringe (1 mL)  Terumo Corporation, Philippines 
 
Tissue Culture Flask (Nuclon
TMΔSurface  Nunc™, Denmark 
75 cm
2 Vented)   
 
Trypsin-EDTA  Sigma-Aldrich, USA 
 
 
 
2.1.6 Transfection 
Item  Supplier 
Biological Safety Cabinet (Gelman BH-2000  Gelman Sciences, Australia 
Cabinet Class II) 
 
Lipofectamine™ LTX Reagent  Invitrogen, Australia 
 
Opti-MEM
® I Reduced Serum Medium  GIBCO™ Invitrogen, Australia   39 
PLUS™ Reagent (3 mg/mL)  Invitrogen, Australia 
 
 
 
2.1.7 Protein Extraction and Quantification 
Item  Supplier 
 
Biological Safety Cabinet (Gelman BH-2000  Gelman Sciences, Australia 
Cabinet Class II) 
 
Cell Scraper (25 cm, 2 position blade)  Sarstedt Inc., USA 
 
Hydrochloric acid (HCl) (37%)  BDH AnalaR, Australia 
 
Microplate (96-Well)  Greiner Bio-One, Germany 
 
Microplate Reader (FLUOstar Optima)  BMG Glass Inc, USA 
 
Multipipette (Socorex Acura 855)  Interpath Services, Australia 
 
Sodium hydroxide (NaOH)  Merck, Germany 
 
Protease Inhibitor Tablet  Roche Diagnostics Corp, USA 
 
Protein Assay Kit (Pierce BCA)  Progen Industries Ltd., USA 
 
Sodium Dodecyl Sulphate (SDS)  BDH Laboratory Supplies, UK 
 
Sonicator (Microson Ultrasonic Cell  Misonic Inc., USA 
Disruptor) 
 
Tris  BDH AnalaR, Australia 
 
Triton X-100  BDH AnalaR, Australia 
 
 
 
2.1.8 Western Blotting 
Item  Supplier 
 
Acetic Acid (CH3COOH)  BDH Merck, Germany 
 
Bromophenol Blue  Fisons Scientific Equipment, UK 
 
Coomassie Brilliant Blue  Fisons Scientific Equipment, UK 
 
QuickPoint
TM Electrophoresis Cell  Novex, USA   40 
Electrophoresis Power Supply (EPS301)  Amersham  Pharmacia  Biotech, 
Sweden 
 
Filter Paper (Novablot)  GE  Healthcare  Life  Sciences, 
Australia 
 
Glycerol  BDH Merck Pty Ltd, Australia 
 
Glycine   ICN Biomedical Inc, USA 
 
Heat Sealer (Impulse HN-300D)  HeatShrink Australia 
 
ß-mercaptoethanol  Sigma-Aldrich, USA 
 
Methanol (CH3OH)  BDH Laboratory Supplies, UK 
 
Shaking platform (Belly Dancer)  Storall Life Science, USA 
 
MOPS SDS Running Buffer NuPage® (20x)  Invitrogen,  Australia 
 
Nitrocellulose Blotting Membranes  Fisher Biotec, Australia 
(Bio Trace NT) 
 
Phosphate Buffered Saline powder (PBS)  Thermo Electron, Australia 
 
Platform Mixer  Ratek Instruments, Australia 
 
Pre-Cast 10 and 12 Well Gels (NuPAGE®   Invitrogen, Australia 
4-12% Bis-Tris Gel) 
 
Protein Standard (MagicMark™ XP)  Invitrogen, Australia 
 
Protein Standard (Novex Sharp  Invitrogen, Australia 
Pre-stained) 
 
Sodium Dodecyl Sulphate (SDS)  BDH Laboratory Supplies, UK 
 
Skim Milk Powder  Woolworths, Australia 
 
Transfer Block (Owl)  Bio-Rad Laboratories, USA   
 
Tris  BDH AnalaR, Australia 
 
NuPAGE
® Transfer Buffer  Invitrogen, Australia 
 
VersaDoc Imaging System 3000  Bio-Rad Laboratories, USA 
 
Western Lightning™ Plus-ECL  Perkin Elmer, USA   
(Enhanced Luminol Reagent Plus,  
Oxidising Reagent Plus)   41 
Antibodies 
β-Actin Goat Polyclonal IgG (200 µg/mL)  Santa Cruz Biotechnology, USA 
 
Donkey Anti-Goat IgG Horseradish  Santa Cruz Biotechnology, USA 
Peroxidase Conjugate (200 µg/0.5 mL) 
 
Rabbit Polyclonal GFP Antibody (0.5 µg/mL)  Abcam, USA 
 
Goat Anti-Rabbit IgG Horseradish  Santa Cruz Biotechnology, USA 
Peroxidase Conjugate (200 µg/0.5 mL) 
 
 
 
2.1.9 Iron and Zinc Uptake/Release Assays 
 
Item  Supplier 
 
Bovine Serum Albumin (BSA)  Thermo Electron, Australia  
 
Counting Test Tubes (Plastic Injector &  Techno-Plas, Australia 
Blow Moulders) 
 
Desferrioxamine mesylate (DFO)  Sigma, USA 
 
Diethylenetriaminepentaacetic acid  Sigma-Aldrich, USA 
(DTPA) 
 
Gamma Counter (Wallac Wizard 3” 1480)  Perkin Elmer, Australia 
 
Hyrdochloric acid (HCl) (37 %)  BDH AnalaR, Australia 
 
N, 2-Hydroxyethylpiperazine-N'-2-ethane  GIBCO™ Invitrogen, Australia 
sulfonic acid (HEPES)   
 
Iron (III) chloride hexahydrate (FeCl3)  Sigma-Aldrich, USA 
 
Iron-59 (Radioisotope)  Perkin Elmer, Australia 
 
Sodium hydroxide (NaOH)  Merck, Germany 
 
Trisodium Citrate  BDH AnalaR, Australia 
 
Triton X-100  BDH AnalaR, Australia  
 
Zinc chloride (ZnCl2)  Sigma-Aldrich, USA 
 
Zinc-65 (Radioisotope)  Perkin Elmer, Australia 
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2.1.10 General Materials and Equipment 
Centrifugation & Vortexing 
Item  Supplier 
 
Centrifuge (Capsulefuge Tomy PMC-060)  Quantum Scientific, Australia 
 
Centrifuge (Eppendorf Mini Spin)  Crown Scientific, Australia 
 
Centrifuge (Eppendorf 5424)  Quantum Scientific, Australia 
 
Centrifuge (Megafuge 1.0R)  Heraeus Sepatech, Germany 
 
Centrifuge (Sigma 4K15)  John Morris Scientific, Australia 
 
Vortex (MT 17V)  Chiltern Scientific 
 
 
 
Water 
 
Distilled Water, DNAse & RNAse Free, was supplied by GIBCO™ Invitrogen, 
 
Australia and Milli-Q (deionised) water was prepared using a Milli-Q Plus Water 
 
Purification System (Millipore, Australia). 
 
 
 
Sterilization 
 
Glassware was soaked in detergent or bleach and washed with deionised water in 
a dishwasher before autoclaving (Atherton, Australia). 
 
 
 
2.2 BUFFERS, REAGENTS, SOLUTIONS AND MEDIA 
 
 
 
Buffers,  reagents,  solutions  and  media  were  prepared  by  weighing  chemicals 
using an ER-120A or Fx-2000 balance (A & D Mercury, Australia), dissolving in 
deionized water and, when required autoclaved (120°C; 15 psi; 20 min, Atherton,   43 
Australia). pH was measured using a Corning 220 pH Meter (Crown Scientific, 
Australia). 
 
2.2.1 Reverse Transcription, RT-PCR and PCR 
 
10 mM dNTPs 
A mix containing 10 mM of each dNTP was prepared by adding 100 µL each of 
100 mM dATP, dCTP, dGTP, and dTTP to 600 µL nuclease free water and stored 
at -20°C. 
 
500 mM EDTA 
0.186 g EDTA was dissolved in 50 mL Milli-Q H2O by adjusting the pH to 8.0 
and adding additional Milli-Q H2O to a final volume of 100 mL. 
 
1 Kb Plus Molecular Weight Marker 
1 µL of 1 Kb Plus DNA Ladder was added to 2 µL 6x loading dye and nuclease 
free H2O to 10 µL and stored at -20°C. 
 
Primers 
RT-PCR ZnT forward and reverse primers were designed using the web-based 
computer programme Primer 3
65 in order to amplify the four putative isoforms. 
qF1/qR1 amplifies a long coding isoform (LCI), qF4/qF1 amplifies LCI as well as 
the short coding isoform (SCI) which is 269 bases shorter than the LCI, qF2/qR2 
amplifies  a  short  untranslated  region  (SUI)  and  qF3/qR3  amplifies  a  long   44 
qF1 
qR3 
qF2 
qR1  qR2 
qF3  qF4 
 
603 nucleotides 
5’  3’ 
untranslated region (LUI) (Figure 2.1; Table 2.1). qF1/qR1 and qF4/qR1 RT-PCR 
primers were designed by Ross Graham from the Iron Metabolism Laboratory, 
School of Medicine and Pharmacology, Fremantle Hospital Campus, University 
of Western Australia (Table 2.1). ZnT-1 PCR primers were designed as described 
in Section 2.4.6.1 by Ross Graham. 
 
 
 
 
Figure 2.1: ZnT-1 Primer Sites. Primer sites for the 4 isoforms are shown as 
well  as  the  coding  sequence      untranslated  region      and  intron  
(adapted from NCBI
66). 
 
 
 
1x SYBR Green 
A 1x SYBR Green solution was prepared by adding 100 µL 10x SYBR Green to 
900 µL nuclease free water and stored at -20°C. 
 
50x TAE Buffer 
121 g Tris was dissolved in 300 mL Milli-Q H2O before adding 29 mL Glacial 
Acetic Acid and 50 mL EDTA (500 mM). The volume was made up to 500 mL 
with Milli-Q H2O before adjusting the pH to 8.0 and autoclaving. 
 
1x TAE Buffer 
200 mL of 50x TAE Buffer was added to 9.8 L Milli-Q H2O.   45 
1x TE Buffer pH 7.5 
1 mL Tris (1 M) and 20 µL EDTA (500 mM) was added to 90 mL Milli-Q H2O 
and the pH adjusted to 7.5 before adding additional Milli-Q H2O to a final volume 
of 100 mL and autoclaving. 
 
1 M Tris-HCl pH 7.4 
12 g of Tris was added to 100 mL Milli-Q H2O and the pH was adjusted to 7.4. 
 
2.2.2. Cloning 
 
Competent E. coli DH5-α Cells 
Competent  E.  coli  DH5-α  Cells  were  prepared  as  per  Inoue  et  al.
67  by  Ross 
Graham  or  Carly  Herbison  from  the  Iron  Metabolism  Laboratory,  School  of 
Medicine and Pharmacology, Fremantle Hospital Campus, University of Western 
Australia and storing at -80°C until required. 
 
0.1 M Isopropyl ß-D-1 thiogalactopyranoside (IPTG) 
0.2383 g IPTG was dissolved in a final volume of 10 mL Milli-Q H2O and filter 
sterilised before being aliquoted into 1.5 mL tubes and storing at -20°C. 
 
2 M Glucose Stock 
3.603 g glucose was dissolved in a final volume of 10 mL Milli-Q H2O and filter 
sterilised (0.22 µm). 
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Luria-Bertani (LB) Broth 
4 g Bacto Tryptone, 2 g Yeast Extract and 4 g NaCl was diluted in Milli-Q H2O to 
a final volume of 400 mL and autoclaved after adjusting the pH to 7.0. 
 
LB Agar 
LB Agar was prepared as per LB Broth with the addition of 3 g Bacto Agar. 
 
2 M Mg
2+ Stock 
20.33  g  of  MgCl2.6H2O  and  24.65  g  MgSO4.7H2O  was  dissolved  in  a  final 
volume of 100 mL Milli-Q H2O and filter sterilised (0.22 µm). 
 
SOC 
20 g Bacto Tryptone, 5 g Yeast Extract, 5.8 g NaCl and 1.86 g KCl was diluted in 
980 mL Milli-Q H2O and autoclaved after which 10 mL filter sterilised Mg
2+ (20 
mM) was added along with 10 mL filter sterilised glucose (20 mM). 
 
1x TE Buffer pH 8.0 
1x TE Buffer was made as outlined in section 2.2.1 with the exception of the pH 
being adjusted to 8.0. 
 
X-gal (50 mg/mL) 
0.2 g of X-gal was dissolved in 10 mL DMF and stored in 1 mL aliquots at -20°C 
protected from light. 
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2.2.3 Cell Culture 
 
Dulbecco’s Modified Eagle Medium (D-MEM/F12) 
One powdered Dulbecco‟s Modified Eagle Medium (D-MEM/F12) sachet was 
dissolved in a final volume of 1 L Milli-Q H2O along with approximately 4 g 
NaHCO3 to adjust the pH to 7.4 before being filter sterilised and stored at 4°C. 
 
Cell Culture Medium  
20 mL Foetal bovine serum (FBS) (10%), 2 mL L-glutamine (2 mM), 0.2 mL 
Insulin-Transferrin-Selenium Supplement (1x) and 20 µL Dexamethasone (1mM) 
was  added  to  180  mL  D-MEM/F12  and  stored  at  4°C.  The  medium  was 
supplemented with gentamicin (400 µL of 80 μg/mL) . 
 
10x Phosphate Buffered Saline (PBS) 
9.55 g Phosphate Buffered Saline powder was dissolved in Milli-Q H2O to a final 
volume of 1 L and the pH was adjusted to 7.4 before autoclaving. 
 
1x Phosphate Buffered Saline (PBS) 
1x PBS was made by adding 100 mL 10x PBS to 900 mL Milli-Q H2O, and 
autoclaving. 
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2.2.4 Protein Extraction 
 
1 M NaOH 
4g of NaOH was dissolved in 100 mL Milli-Q H2O. 
 
1x Phosphate Buffered Saline (PBS) 
1x  Phosphate  buffered  saline  was  prepared  as  previously  described  in  section 
2.2.3. 
 
10% Sodium Dodecyl Sulphate (SDS) 
50 g SDS was added to 500 mL Milli-Q H2O. 
 
SDS Lysis Buffer (2% SDS, 50mM Tris-HCl pH 7.4) 
SDS Lysis Buffer was prepared by adding 2 mL 10% SDS to 500 µL 1 M Tris-
HCl  pH  7.4  and  7.5  mL  Milli-Q  H2O  followed  by  dissolving  one  protease 
inhibitor tablet (Chymotrypsin; Pancreas extract; Papain; Pronase; Thermolysin; 
Trypsin)  before storing at -20°C. 
 
Triton/NaOH 
1 mL of 1 M NaOH and 100 µL of Triton X-100 were added to 9 mL Milli-Q 
H2O. 
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2.2.5 Western Blotting 
 
Antibodies 
ß-Actin Antibodies 
5 mL of a 1:1000 concentration of β-Actin Goat Polyclonal IgG (200 µg/mL) 
primary antibody was prepared in PBST and 5 mL of a 1:2000 concentration of 
Donkey  Anti-Goat  IgG  Horseradish  Peroxidase  Conjugate  (200  µg/0.5  mL) 
secondary antibody was prepared in 2% skim milk. 
 
GFP Antibodies 
 5 mL of a 1:1000 concentration Rabbit Polyclonal GFP (0.5 µg/mL) primary 
antibody was prepared in PBST and 5 mL of a 1:2000 concentration of Goat Anti-
Rabbit  IgG  Horseradish  Peroxidase  Conjugate  (200  µg/0.5  mL)  secondary 
antibody was prepared in 2% skim milk. 
 
Blocking Solution 
5% blocking solution was prepared by dissolving 2.5 g of skim milk powder in 50 
mL PBST and storing at 4°C. Similarly a 2% solution was prepared by dissolving 
1 g of skim milk powder to 50 mL PBST. 
 
Coomassie Blue Stain Solution 
Coomassie Blue Stain solution was prepared by adding 1 g Coomassie Brilliant 
Blue to 237.5 mL 95% Methanol, 50 mL Acetic Acid and 212.5 mL Milli-Q H2O. 
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10x  Electrophoresis  Buffer  (0.025  M  Tris  pH  8.3,  0.192  M  Glycine,  0.1% 
SDS) 
 
29 g Tris was added to 1 L Milli-Q H2O along with 144 g glycine and 10 g SDS. 
 
1x Electrophoresis Buffer 
A 1x solution was prepared by adding 100 mL 10x Electrophoresis Buffer to 900 
mL Milli-Q H2O. 
 
Loading Dye 
25 mg Bromophenol Blue was added to 10 mL 1x Electrophoresis buffer. 
 
1x PBS 
1x PBS was prepared as previously described in section 2.2.3. 
 
PBST 
1 mL 20% Tween 20 was added to 500 mL 1x PBS. 
 
4x Sample Buffer 
4x Sample buffer was prepared by combining 1 mL 2.5 M Tris pH 6.8, 2.7 mL 
30% SDS, 4 mL glycerol, 0.3 mL Milli-Q H2O and 0.5 µL Loading Dye and 
stored at -20°C. 2 mL 10% ß-Mercaptoethanol was added just prior to use. 
 
30% Sodium Dodecyl Sulphate (SDS) 
30 g SDS was added to 100 mL Milli-Q H2O.   51 
Transfer Buffer (15% Methanol) 
10 mL of 20x NuPAGE® Transfer Buffer was added to 160 mL Milli-Q H2O 
along with 30 mL of Methanol. 
 
2.5 M Tris, pH 6.8 
30 g of Tris was added to 100 mL Milli-Q H2O and the pH was adjusted to 6.8. 
 
2.2.6 Iron and Zinc Uptake/Release Assays 
 
500 mM Citrate 
1.47 g Trisodium citrate was dissolved in 10 mL Milli-Q H2O. 
 
1 mM FeCl3 
2.7 g of  FeCl3was  dissolved in  10 mL 0.1 M  HCl. Then a 1:10  dilution was 
prepared by adding 10 µL to 9.99 mL of HCl (0.1 M). 
 
 HBSS 
1 sachet of powdered HBSS was dissolved in 1 L Milli-Q H2O and approximately 
1 g NaHCO3 was added to adjust the pH to 7.4 before being stored at 4°C. 
 
1 M HCl 
8.57mL HCl was added to 91.43 mL of Milli-Q H2O. 
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0.1 M HCl 
1 mL 1 M HCl was added to 9 mL Milli-Q H2O. 
 
Iron and Zinc Radioactive Solutions 
An appropriate dilution of 
59Fe and 1 mM FeCl3 or 
65Zn and 1 mM ZnCl2 was 
prepared  in  100-fold  molar  excess  of  Trisodium  citrate  and  added  to  2.8  mL 
standard  uptake/release  medium  described  below.  Dilution  depended  on  the 
specific activity of the radioisotope. 
 
Standard Uptake/Release Medium 
DMEM was made as previously described in  Section 2.2.3 with 11.92 g HEPES 
(final  concentration,  50  mM),  and  the  pH  was  adjusted  to  7.2.  Bovine  serum 
albumin  (BSA)  was  added  just  prior  to  use  to  the  required  amount  of 
DMEM/HEPES to a final concentration of 2% and incubated at 37°C to dissolve 
BSA. 
 
Release medium supplemented with DFO 
28 µL DFO (10 mM) was added to 2.8 mL standard uptake/release medium to 
give a final concentration of 100 µM. 
 
Release Medium supplemented with DTPA  
11.02 µL DTPA (25.4mM) was added to 2.8 mL standard uptake/release medium 
to give a final concentration of 100 µM. 
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Triton/NaOH 
Triton/NaOH was prepared as previously described in Section 2.2.4. 
 
1 mM ZnCl2 
1.36 g of ZnCl2was dissolved in 10 mL 0.1 M HCl. Then a 1:10 dilution was 
prepared by adding 10 µL to 9.99 mL of HCl (0.1 M). 
 
2.3 ANIMAL TISSUE AND CELL LINES 
Wild type AKR mice were fed a control diet of mouse chow (Specialty Feeds, 
Glen  Forrest,  WA)  containing  0.01%  Fe,  an  iron-loaded  diet  containing  2% 
carbonyl  Fe  or  an  iron  deficient  diet  containing  0.001%  Fe.  Hfe  knockout, 
TfR2(Y245X) mutant and double mutant (Hfe -/-/TfR Y245X) mice were fed a 
control diet. Liver tissue was collected from mice by Ross Graham and Anita 
Chua  (Iron  Metablolism  Laboratory,  School  of  Medicine  and  Pharmacology, 
Fremantle  Hospital  Campus,  University  of  Western  Australia),  snap  frozen  in 
liquid nitrogen and stored at -80°C until required. 
 
AML12 cells used in this study are a mouse hepatocyte cell line supplied by the 
American Type Culture Collection, USA. Cells were thawed and subcultured into 
a 75 cm
2 flask by Carly Herbison. 
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2.4 METHODS 
 
2.4.1   Extraction of RNA from Liver Tissues 
Tissue (40 – 60 mg) was added to a 2 mL microcentrifuge tube containing 400 µL 
cold TRI Reagent and homogenized using an Ultra-Turrax homogenizer. Then a 
further  400  µL  cold  TRI  reagent  was  added  to  the  microcentrifuge  tube  and 
incubated at room temperature (RT) for 5 min. After the addition of 80 µL of BCP 
the tubes were vigorously shaken for 30 s before incubating (10 min, RT). The 
tubes were centrifuged (16000g; 15 min; 4°C) and the aqueous phase containing 
the RNA was  transferred to  a 1.5 mL low adhesion  microcentrifuge tube. An 
equal volume of isopropanol was added to pellet the RNA and the tube was mixed 
by inverting. After incubating for 10 min at RT the tube was centrifuged (16000g; 
5 min; 4°C) to precipitate the RNA and the supernatant removed. The pellet was 
washed with 200 µL 75% ethanol, dislodged and centrifuged (8000g; 5 min; 4°C). 
The supernatant was removed and the pellet was air dried before dissolving in 50 
µL of nuclease free water (15 min; 55°C). 
 
2.4.2   DNase Treatment of Extracted RNA and Quantification 
Following  RNA  extraction  the  samples  were  treated  with  DNase  to  remove 
genomic DNA. A 0.1 volume of 10x DNase 1 buffer and rDNase (2 units) was 
added to the RNA sample, mixed gently and incubated for 30 min at 37°C). To 
terminate the reaction, DNase Inactivating Reagent was resuspended and a 0.1 
volume was added to the samples and incubated (2 min; RT) with occasional 
mixing. Centrifugation (10000g; 90 s; RT) precipitated the DNase Inactivating 
Reagent  and  the  supernatant  was  transferred  to  a  clean  0.6  mL  low  adhesion   55 
microcentrifuge tube and stored at -80°C until required. The RNA concentration 
was determined by diluting 2 µL of the sample with 98 µL of nuclease free water 
(1:50  dilution)  and  measuring  the  absorbance  at  260  nm  and  280  nm  by 
spectrophotometry. Samples with a 260/280 ratio of 1.8 – 2 were considered to be 
of sufficient purity and used for further analysis where as samples with higher or 
lower ratios were discarded and RNA was re-extracted from additional samples. 
RNA concentration (µg/µL) = (A260nm x 40 µg/m x 50)/1000. 
 
2.4.3   Gel Electrophoresis of RNA 
RNA integrity was examined by agarose gel electrophoresis. A 1% agarose gel 
was  prepared  in  1x  TAE  buffer  and  slightly  cooled  before  adding  ethidium 
bromide (0.16 µg/mL). The agarose was poured into a gel tray and allowed to set 
with the appropriate comb in place. RNA samples were prepared by adding 1.5 µg 
of RNA up to 10 µL of nuclease free water and heated (70°C; 1 min) before being 
placed on ice. 5 µL of a 1 Kb Plus molecular weight marker was loaded into the 
first well. RNA samples were loaded into remaining wells after mixing with 2 µL 
of 6x loading dye and electrophoresed in 1x TAE buffer (1 h, 120 v). The gel was 
visualized on a UV transilluminator to verify the presence of the 28S and 18S 
bands. 
 
2.4.4   Reverse Transcription of RNA 
RNA was reverse transcribed to generate complementary DNA (cDNA) in full or 
half reactions depending on the amount of cDNA required.  For a full reaction 2 
µg of RNA was diluted in nuclease free water to a final volume of 10 µL. A 
master mix consisting of Oligo dTs (0.5 µg) and dNTPs (0.5 mM) in nuclease free   56 
water to a final volume of 3.5 µL per RNA sample was prepared and added to 
each sample before denaturing in a Thermal Cycler (65°C; 5 min) and allowed to 
cool in a metal cooling block for a minimum of 4 min. 6.5 µL of a master enzyme 
mix was added to each sample (200U Superscript III reverse transcriptase, 20U 
RNasin, 5 mM DTT, 1X reverse transcription reaction buffer) and returned to the 
Thermal Cycler where cDNA was synthesised (50°C; 60 min) followed by an 
enzyme inactivation cycle (70°C; 15 min). cDNA was stored for a maximum of 3 
days at 4°C. 
 
2.4.5   Real-Time Polymerase Chain Reaction (PCR) 
Real-time  PCR  was  undertaken  on  cDNA  samples  and  plasmid  standards  of 
known copy numbers (10
1 to 10
10) to amplify the gene of interest to quantify 
mRNA  expression.  A  master  mix  was  prepared  for  each  gene  studied  and 
consisted of 0.25 mM dNTPs, 0.25 µM each forward and reverse primer (Table 
2.1), 3 mM MgCl2, 0.5 U Platinum Taq Polymerase, 0.1x SYBR Green and 1x 
reaction buffer in nuclease free water to a final volume of 19 µL per sample and 
aliquoted into tubes to which 1 µL of cDNA or standard was added. The samples 
underwent  PCR  in  a  Corbett  Research  Real-Time  Cycler  (RG  2000  or  3000) 
according to the cycling parameters outlined in Table 2.2. 
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Table: 2.1 Primers used for real-time RT-PCR of Genes (including Annealing 
temperature (TA), Melt Curve Peak and Product Size)  
 
Gene  Primer Sequence (5’- 3’)  TA 
(°C) 
Product Size 
(bp) 
       
ZnT-1 
(LCI) 
qF1 CCAACACCAGCAATTCCAAC 
qR1 AAAAGACCAAGGCATTCACG 
 
59  228 
ZnT-1 
(SCI) 
qF4 GAACGCCATCTTCCTCACG 
qR1 AAAAGACCAAGGCATTCACG 
 
59  273 (SCI) 
542 (LCI) 
ZnT-1 
(SUI) 
qF2  GAGAAGAAGGCCAGGAGGAC 
qR2 CGACCAGACAAGGACTTCAA 
 
59  210 
ZnT-1 
(LUI) 
qF3 CAGTCATTTTCACTGGCACAA 
qR3 GACAGGACCAACTCGAGAGC 
 
59  234 
ß-actin
68  F CTGGCACCACACCTTCTA  
R GGTGGTGAAGCTGTAGCC 
 
59  352 
Hamp
69  F CCTATCTCCATCAACAGATG 
R AACAGATACCACACTGGGAA  
 
53  171 
Fpn
70  F TTGCAGGAGTCATTGCTGCTA 
R TGGAGTTCTGCACACCATTGAT 
 
53  120 
TfR1
68  F TTCCTACATCATCTCGCTTAT 
R CATAGTGTTCATCTCGCCAGA 
 
53  216 
Dmt1
71 
(Total) 
F TCTATCGCCATCATCCCCACCC 
R TCCACAGTCCAGGAAAGACAGACCC 
 
58  375 
Zip14A
72  F  TTCCTCAGTGTCTCACTGATTAA 
R  GGAAAAGGGCGTTAGAGAGC       
54  142 
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Table 2.2: Real-Time PCR Cycling Parameters 
 
Steps  Temperature 
(°C) 
Time (seconds)  Number of 
Cycles 
Initial Denaturation  95  300  1 
Denaturation 
Annealing 
Extension 
95 
50 – 60 
72 
15 
20 
20 
 
40 
Hold  72  30  1 
Melting Curve  72 – 99  5  1 per 1°C 
increment 
Hold  40  30  1 
 
 
In addition RT-PCR was used to screen LR reaction transformants and pGEM-T 
transformants  to  determine  whether  they  contained  the  correct  plasmid.  The 
reaction was performed as described above with supernatant from the overnight 
culture (Section 2.4.9.3) using qF1/qR1 primers for the LR reaction and qF2/qR2 
and qF3/qR3 primers for the pGEM-T reaction (Table 2.1). 
 
2.4.6   Polymerase Chain Reaction of cDNA and Plasmids 
PCR was performed on cDNA from RNA extracted from wild-type mouse liver 
tissue  for  the  purpose  of  creating  expression  clones  and  to  generate  plasmid 
standards. In addition PCR was used to screen transformed colonies and confirm 
the  existence  of  the  plasmid.  All  reactions  were  carried  out  in  0.2  mL  low 
adhesion nuclease free tubes in 20 µL reactions in a PTC-100TM thermal cycler. 
 
2.4.6.1 Polymerase Chain Reaction of ZnT-1 Coding Sequence for Cloning 
Forward  and  reverse  primers  were  designed  using  the  a  web-based  computer 
programme Primer 3
65 with attB sites to facilitate cloning into a Gateway
® vector   59 
Primers were designed by Ross Graham to amplify the ZnT-1 coding sequence. 
They included four guanine (G) residues at the 5‟ end followed by a 25 base 
sequence known as the attB1 site and attB2 site (underlined) for forward and 
reverse  primers  respectively,  followed  by  20  base  gene-specific  sequences. 
Furthermore two additional nucleotides were included (highlighted) to maintain 
the proper reading frame with the attB1 region once the PCR product was fused in 
frame with an N-terminal tag. In addition shorter primers were designed without 
attB sites (Table 2.3). 
 
Table 2.3: Primers used for PCR of ZnT-1 
Primer  Primer Sequence (5’ – 3’)  Product Size 
cF 
 
cR 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
ATGGGCTGCTGGGGCCGCAA 
GGGGACCACTTTGTACAAGAAAGCTGGGTC 
CTCACAAAATGATTCGGGC 
 
 
1574 
cFsh1 
cRsh 
ATGGGCTGCTGG GGCCGCA 
CTCACAAAGATGATTCGGGC 
 
1513 
cFsh2  GCTTCGGTCCGATGCTC 
(use with cRsh1) 
1676 
 
 
To determine the optimal conditions for the reaction it was necessary to undertake 
several PCR reactions to optimise conditions such as DNA Polymerases, Mg
2+ 
and primer concentrations and PCR enhancing agents such as PCR enhancer, Q 
Solution,  DMSO  and  Glycerol.  PCR  enhancers  can  facilitate  efficient 
amplification of problematic templates or GC-rich sequences, Q Solution changes 
the melting behaviour of DNA
73, and DMSO and Glycerol not only lower the   60 
primer  and  template  melting  temperature  (TM)  but  also  aid  in  relaxing  GC 
secondary structures
74; 75.  
 
Generally, for all reactions, a master mix was prepared containing 0.2 mM – 2 
mM dNTPs, 0.25 µM – 4 µM of each forward and reverse primer, 2 mM – 3 mM 
Mg
2+, 0.5 – 5 U DNA Polymerase, 1x reaction buffer and plus or minus one or 
more of the abovementioned PCR enhancing agents in nuclease free water to a 
final volume of 17.5 µL to 19 µL per sample and aliquoted into tubes to which     
1 µL – 2.5 µL of cDNA was added. All reactions underwent PCR according to the 
cycling parameters listed in Table 2.4. In each instance cycling parameters and the 
addition and concentration of reagents and enhancers was determined from results 
of the preceding reaction as well as in accordance with reagent specifications.  
 
Ultimately ZnT-1 was amplified using 0.6 mM dNTPs, 0.25 µM of each forward 
and  reverse  primer,  2  mM  Mg
2+,  1x  reaction  buffer,  1x  PCR  enhancer,  5% 
DMSO,  5  units  Pfx50  and  2  µL  cDNA  and  were  subjected  to  an  initial 
denaturation cycle (94°C, 2 min) followed by 35 cycles of denaturation (94°C, 30 
s);  annealing  (54°C,  30  s);  and  extension  (68°C,  100  s)  before  a  final  5  min 
extension step at 68°C and holding at 4°C. 
 
Table 2.4: PCR Cycling Parameters 
 
Steps  Temperature 
(°C) 
Time (seconds)  Number of 
Cycles 
Initial Denaturation  94 – 95  120  1 
Denaturation 
Annealing 
Extension 
94 – 95 
50 – 68 
68 – 72 
30 
30 
90 – 100 
 
35 
Final Extension  68 – 72  300 – 600  1 
Hold  4  ∞  1   61 
2.4.6.2. Polymerase Chain Reaction of ZnT-1 for Plasmid Standards 
PCR was also used to amplify a fragment of the ZnT-1 gene to create plasmid 
standards  to  be  used  in  RT-PCR.  Two  sets  of  primers  were  used  to  amplify 
regions specific to different mRNA isoforms qF2/qR2 and qF3/qR3 (Figure 2.1; 
Table 2.1). A master mix was prepared as described in Section 2.4.5 without 1x 
SYBR. Samples were then subjected to an initial denaturation cycle (94°C, 2 min) 
followed by 35 cycles of denaturation (94°C, 30 s); annealing (58°C, 30 s); and 
extension (72°C, 1 min)  before a final 2 min extension step at 72°C and holding 
at 4°C. 
 
In addition PCR was used to screen BP and LR reaction transformants (Section 
2.4.9.1; 2.4.9.3) in order to determine whether they contained the correct plasmid. 
Primers  used  were  cF/cR  and  cFsh1/cRsh  for  BP  and  LR  transformants 
respectively. A master mix was prepared as described in Section 2.4.5 with the 
following exceptions: 2.5 mM MgCl2, 1x PCR Enhancer, 5% DMSO and 1 µL of 
supernatant  from  the  overnight  culture  (Section  2.4.9.1;  2.4.9.3)  was  added. 
Samples  were  then  subjected  to  an  initial  denaturation  cycle  (94°C,  2  min) 
followed by 35 cycles of denaturation (94°C, 30 s); annealing (54°C, 30 s); and 
extension (72°C, 100 s) before a final 5 min extension step at 72°C and holding at 
4°C. 
 
2.4.7   Agarose Gel Electrophoresis of PCR Products 
The procedure was performed as described in Section 2.4.3, however, 15 – 20 µL 
of the product was loaded into each well after mixing with 2 – 3 µL of 6x loading 
dye and electrophoresed for 40 min to 1 h.    62 
2.4.8   Purification of PCR Products and Gel Extraction 
The  PCR  products  were  prepared  for  cloning  by  purifying  the  product  or 
extracting and purifying a band of the correct size cut from an agarose gel. PCR 
purification was performed using the PureLink
® PCR Purification Kit (Invitrogen) 
or  the  ChargeSwitch
®-Pro  PCR  Clean-up  Kit  (Invitrogen)  according  to  the 
manufacturer‟s instructions and gel extraction and purifications were performed 
using  the  QIAquick
®  Gel  extraction  Kit  (QIAGEN)  as  per  the  manufacturer‟s 
instructions. Briefly, samples were added to a column along with a binding buffer 
and  centrifuged  (10,000g,  1  min)  to  allow  the  DNA  to  bind  to  the  column. 
Addition of a wash buffer and further centrifugation (10,000g, 1 min) removed 
any contaminants after which the DNA was eluted in 50 µL buffer (20 mM Tris-
HCl,  pH  8.5).  DNA  concentrations  were  measured  by  spectrophotometry  as 
previously described in Section 2.4.2 
 
2.4.9   Cloning of Znt-1 into Vectors 
The purified ZnT-1 gene was cloned using Gateway
® Technology (Invitrogen) 
vectors to create an expression clone. In addition, a fragment of ZnT-1, amplified 
as  described  in  Section  2.4.6.2,  was  cloned  into  the  pGEM
®-T  Easy  Vector 
(Promega) to generate a plasmid standard. 
 
The creation of an expression clone was achieved via a two-step cloning process; 
the BP Clonase and LR Clonase reactions generated entry clones and expression 
clones respectively.  
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ZnT-1  ccdB 
attB  attB  attP  attP 
attL  attL  attR  attR 
ZnT-1 
pDONR221 
+ 
+  ccdB 
pENTR221-ZnT-1  By-product 
attB-flanked PCR product 
2.4.9.1 Construction and Amplification of pENTR221-ZnT-1 Entry Clones 
To  create  pENTR221-ZnT-1  the  purified  attB-ZnT-1  product  (103.88  ng)  was 
combined  with  Gateway
®  pDONR221  vector  (150  ng),  1.25x  BP  Clonase 
Reaction Buffer and TE Buffer (pH8.0) to a final volume of 8 µL. BP Clonase 
Enzyme was thawed on ice (2 min) and after vortexing (twice, 2 s) 2 µL was 
added to the reaction and allowed to incubate (25°C, 2 h). BP Clonase facilitates a 
recombination reaction between att sites on the interacting DNA molecules and 
the presence of the ccdB gene in the pDONR221 vector allows negative selection 
by inhibiting growth of E. coli carrying the pDONR221 vector or the by-product 
molecules retaining the ccdB gene
2 (Figure 2.2). The BP Clonase enzyme was 
then digested to prevent further recombination reactions by adding Proteinase K 
(2 µg) and incubating (37°C, 10 min) the reaction was either stored (-20°C) or 
used immediately to transform E. coli DH5-α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: BP Reaction. Recombination between attB-flanked PCR product and 
Gateway
®  pDONR221  vector  generates  pENTR221-ZnT-1  adapted  from 
Invitrogen
76. 
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A 1.5 µL aliquot of the BP Clonase recombination reaction was added to 100 µL  
of competent E. coli DH5-α cells and incubated for 30 min on ice. The cells were 
heat shocked (42°C, 30 s) and immediately transferred to ice before the addition 
of 900 µL SOC medium. After incubating with shaking (37°C, 1 h, 250 rpm) a 
glass spreader was used to spread 100 µL and 20 µL of the reaction onto LB agar 
plates  containing  kanamycin  (50  µg/mL)  to  select  the  growth  of  colonies 
containing plasmids expressing the km-resistance gene. Following an overnight 
incubation at 37°C a single colony was picked from the plate with a disposable 
loop  and  used  to  inoculate  both  10  µL  of  nuclease  free  water  in  a  1.5mL 
microcentrifuge tube and 8 mL LB containing kanamycin (50µg/mL). The sample 
was  boiled  (95  °C,  5  min)  before  centrifuging  (10,000g,  1  min)  and  the 
supernatant used in a PCR reaction as described in Section 2.4.6. The products 
were analysed by agarose gel electrophoresis (Section 2.4.7) to verify if bacterial 
colonies contained the correct product.  
 
The  8  mL  LB  was  incubated  overnight  with  shaking  (37°C,  250  rpm)  and 
pENTR221-ZnT-1 was extracted using the FastPlasmid
™ Mini Kit (Eppendorf) or 
the  QIAprep
®  Spin  Miniprep  Kit  (QIAGEN)  according  to  the  manufacturer‟s 
instructions. Briefly, cells were lysed and after precipitating the protein the tubes 
were centrifuged (16,000g, 1 min) to pellet the denatured protein. The supernatant 
was added to the column allowing the DNA to bind and the DNA was washed 
with a solution containing 30% isopropanol to remove any remaining impurities 
before  eluting  in  50  µL  buffer  (10  mM  Tris-HCl  pH  8.0,  0.1  mM  EDTA). 
pENTR221-ZnT-1 DNA concentration was quantitated by spectrophotometry, as 
previously described in Section 2.4.2 and stored at -20°C.   65 
2.4.9.2 Sequencing of pENTR221-ZnT-1 Entry Clones  
pENTR221-ZnT-1 entry clones were sequenced to definitively confirm the correct 
gene was cloned and determine whether the sequence was free from mutations. 
Two reactions, one forward and one reverse, were prepared by taking an aliquot 
containing 400 ng of plasmid and combining with nuclease free water to a final 
volume of 15 µL in a 1.5 mL microcentrifuge tube. The reactions were sent to The 
Gandel  Charitable  Trust  Sequencing  Centre,  Monash  Institute  of  Medical 
Research, Melbourne who carried out DNA sequencing with the M13 Fwd and 
“Reverse” primers using the Dideoxy method.  
 
The  chromatogram  was  reviewed  using  the  CodonCode  Aligner
77  computer 
programme and the forward and reverse DNA sequence files were aligned against 
the  NCBI  NM_009579.3  mRNA  sequence  using  Sequence  Analysis
78.  The 
complete coding sequence was determined by aligning the forward and reverse 
sequences and translated to the protein sequence using Sequence Analysis after 
which  it  was  aligned  against  the  NCBI  NP_033605.1  protein  sequence  and 
checked for differences. 
 
2.4.9.3 Construction of Expression Clones 
The  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1  expression  clones 
were constructed by combining 300 ng of the pENTR221-ZnT-1 entry clone with 
150  ng  of  Gateway
®  destination  pcDNA6.2/N-EmGFP-Dest  or  pT-REx-DEST 
vectors respectively along with 1.25x LR Clonase Reaction Buffer and TE Buffer 
(pH8.0) to a final volume of 8 µL. LR Clonase Enzyme was thawed on ice (2 min) 
and after vortexing (twice, 2 s) 2 µL was added to the reactions and allowed to   66 
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incubate  (25°C,  2  h).  As  per  the  BP  reaction,  the  LR  reaction  uses  a 
recombination  reaction  (Figure  2.3).  To  digest  the  LR  Clonase  enzym e  and 
prevent further recombination reactions, Proteinase K (2 µg) was added and after 
incubating  (37°C,  10  min)  the  reactions  were  either  stored  (4°C)  or  used 
immediately to transform E. coli DH5-α. 
 
 
 
 
 
 
 
 
 
Figure  2.3:  LR  Reaction.  Recombination  between  pENTR221-ZnT-1  and 
Gateway
®  pcDNA6.2/N-EmGFP-Dest  vector  generates  pcDNA/GW-N-
EmGFP/ZnT-1 adapted from Invitrogen
76. 
 
 
 
A 1.5 µL aliquot of the LR Clonase recombination reactions were added to 100 
µL  of  competent  E.  coli  DH5-α  cells  in  1.5  mL  microcentrifuge  tubes  and 
incubated  for  30  min  on  ice.  The  cells  were  heat  shocked  (42°C,  30  s)  and 
immediately transferred to ice before the addition of 900 µL SOC medium. After 
incubating with shaking (37°C, 1 h, 250 rpm) a glass spreader was used to spread 
100 µL or 20 µL of the reactions  on to  LB  agar plates  containing  ampicillin 
(100µg/mL) to ensure the growth of colonies containing plasmids expressing the 
amp-resistance gene. Following an overnight incubation at 37°C a single colony 
was picked from the plate with a disposable loop and used to inoculate both 10 µL   67 
of nuclease free water in a 1.5mL microcentrifuge tube and 8 mL LB containing 
ampicillin  (100  µg/mL).  The  sample  was  boiled  (95  °C,  5  min)  before 
centrifuging (10,000g, 1 min) and the supernatants used in RT-PCR and PCR 
reactions as described in Sections 2.4.5 and 2.4.6. For RT-PCR reactions, the melt 
curve  was  analysed  to  verify  amplification  of  a  single  product  and  for  PCR 
reactions  the  products  were  screened  by  agarose  gel  electrophoresis  (Section 
2.4.7) to verify that bacterial colonies contained the correct sized product. 
 
After an overnight incubation with shaking (37°C, 250 rpm) the pcDNA/GW-N-
EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1  plasmids  were  extracted  using  the 
FastPlasmid
™  Mini  Kit  (Eppendorf)  or  the  QIAprep
®  Spin  Miniprep  Kit 
(QIAGEN) according to the manufacturer‟s instructions as described in Section 
2.4.9.1. The concentration was quantitated by spectrophotometry as previously 
described  in  Section  2.4.2  and  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-
REx/GW/ZnT-1 were stored at -20°C.  
 
pcDNA/GW-N-EmGFP/ZnT-1 and pT-REx/GW/ZnT-1 was used to transform E. 
coli  DH5-α  as  previously  described  (Section  2.4.9.3),  spread  on  LB  plates 
containing  ampicillin  (100  µg/mL),  incubated  overnight  (37°C)  and  starter 
cultures  were  prepared  by  inoculating  4  mL  LB  containing  ampicillin  (100 
µg/mL).  After  an  8  h  incubation  period  (37°C,  250  rpm)  the  cultures  were 
expanded by inoculating 200 mL LB containing ampicillin (100 µg/mL) with 400 
µL of the starter culture (1:1000 dilution) and incubated with shaking (37°C, 250 
rpm, 12 h). A RT-PCR was performed (Section 2.4.5), using supernatant derived   68 
from  the  starter  cultures  and  the  melt  curve  was  analysed  to  screen  for 
pcDNA/GW-N-EmGFP/ZnT-1 and pT-REx/GW/ZnT-1. 
 
Following  incubation  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1 
were  extracted  and  purified  using  the  PureLink
™HiPure  Plasmid  Filter 
Purification Kit (Invitrogen) according to the manufacturer‟s instructions. In brief, 
cells were lysed and after precipitating the protein (Potassium acetate solution) the 
lysate was loaded on to an anion-exchange column allowing the DNA to bind. 
The  DNA  was  washed  with  a  sodium  acetate/NaCl  solution  to  remove  any 
remaining impurities before eluting by gravity flow under high salt conditions 
with 15 mL of buffer. The DNA was precipitated with isopropanol (15,000g, 30 
min, 4°C) and washed with 70% ethanol (15,000g, 5 min, 4°C) after which the 
pellet was air dried and resuspended in 500 µL TE Buffer (10mM Tris-HCl pH 
8.0,  0.1mM  EDTA).  The  concentration  was  quantitated  by  spectrophotometry 
(Section 2.4.2) and pcDNA/GW-N-EmGFP/ZnT-1 and pT-REx/GW/ZnT-1 were 
stored at -20°C.  In addition glycerol stocks was prepared by pelleting 3 mL of the 
culture (3,000g, 5 min), resuspending it in 25% glycerol (1 mL 75% LB, 25% 
glycerol, 100 µg/mL ampicillin) and storing at -80°C. 
 
2.4.9.4 Generation of Plasmid Standards 
To create plasmid standards for RT-PCR of the SUI and LUI isoforms a fragment 
of  ZnT-1  corresponding  to  each  of  the  isoforms  was  cloned  into  pGEM-T 
(Promega). 10.5 ng and 11.75 ng of the purified SUI and LUI PCR product was 
combined with pGEM
®-T Easy Vector (50 ng), 1x Rapid Ligation Buffer, and 5U 
T4  DNA  Ligase  to  a  final  volume  of  10  µL  and  incubated  at  4°C.  After  an   69 
overnight  incubation  a  2  µL  aliquot  of  each  reaction  was  added  to  a  1.5  mL 
microcentrifuge tube on ice to which 50 µL of E. coli DH5-α was added. The 
reactions  were mixed gently and incubated on  ice (20 min) before being heat 
shocked (42°C, 50 s) and immediately returned to ice for 2 min. 950 µL of SOC 
was added to each reaction and after 90 min incubation with shaking (37°C, 150 
rpm) 100 µL of each reaction was spread on LB plates containing ampicillin (100 
µg/mL), X-gal (1 mg) and IPTG (10 µM). The plates were incubated overnight at 
37°C and a single colony was picked from the plate and grown overnight (37°C, 
200 rpm) in 5 mL LB containing ampicillin (100 µg/mL). Plasmids were then 
extracted  using  the  FastPlasmid
™  Mini  Kit  (Eppendorf)  according  the 
manufacturer‟s instructions as briefly described in Section 2.4.9.1). A RT-PCR 
was carried out (Section 2.4.5.) at the same time using supernatant derived from 
the overnight culture as previously described. In order to confirm the plasmid was 
correct the melt curve was examined and PCR products were analysed by agarose 
gel electrophoresis as described in Section 2.4.7. 
 
A  100  µL  aliquot  of  the  overnight  culture  was  diluted  (1:500)  in  50  mL  LB 
containing ampicillin (100 µg/mL) and incubated (37°C, 300 rpm). Following an 
overnight incubation the plasmids were extracted using the QIAGEN
® Plasmid 
Purification Kit (QIAGEN) as per the manufacturer‟s instructions. Briefly, cells 
were lysed and after precipitating the protein the tubes were centrifuged (20,000g, 
30 min, 4°C) and (20,000g, 15 min, 4°C) to pellet the protein. The supernatant 
was applied to the QIAGEN-tip allowing binding of plasmid DNA to the anion-
exchange resin by gravity flow after which the DNA was washed (1 M NaCl; 50 
mM MOPS, pH 7; 15% isopropanol) to remove any remaining impurities before   70 
eluting by gravity flow with 5 mL buffer (1.25 M NaCl; 50 mM Tris-Cl, pH 8.5; 
15%  isopropanol)  after  which  the  DNA  was  precipitated  with  isopropanol 
(15,000g, 30 min, 4°C) and washed with 70% ethanol (15,000g, 10 min, 4°C). 
The pellet was allowed to air dry before being resuspended in 100 µL TE Buffer 
(10 mM Tris-HCl pH 8.0, 0.1 mM EDTA). The concentration was quantitated by 
spectrophotometry, as previously described and plasmid standards were generated 
by  preparing a serial  dilution of known copy numbers  by calculating  mass of 
plasmid (ng) in 10
11 copies where 1 µg of 1000 bp DNA (plasmid + insert) = 
1.52pmol. Plasmid DNA was stored at -20°C. In addition a glycerol stock was 
prepared as previously described and stored at -80°C. 
 
2.4.10 Cell Culture of AML12 Cells 
AML12  cells  were  subcultured  when  they  reached  approximately  80% 
confluency. Medium was aspirated from the tissue culture flask and the cells were 
washed  with  10  mL  PBS  to  remove  traces  of  serum  which  contains  trypsin 
inhibitor. The cells were incubated at 37°C with 2 mL of Trypsin-EDTA until 
they detached from the flask. 10 mL medium was added to neutralise the trypsin 
and the cell suspension was transferred to a 15 mL tube and centrifuged at room 
temperature (300g, 3 min). The pellet was resuspended in 1 mL of medium using 
a syringe and needle to separate the clumps of cells and an additional 9 mL of 
medium was added to the flask. The cell suspension was mixed by inverting and a 
cell  count  was  performed  using  a  haemocytometer.  8.0  x  10
5  cells  were 
subcultured in to a sterile 75 cm
2 tissue culture flask containing 10 mL cell culture 
medium  containing  gentamicin  and  incubated  at  37°C  in  5%  CO2/95 
% O2 cell incubator. Medium was replaced on day four and cells were subcultured   71 
into new 75 cm
2 flasks every seven days. In addition, cells were seeded into 6 or 
12 well plates at a density of 3.5 x 10
5 in 1 mL of medium and 7.5 x 10
5 cells per 
well in 2 ml of medium for 6 and 12 well plates respectively and allowed to 
incubate at 37°C for 24 hours.  
 
2.4.11 Transfection of AML12 Cells 
AML12 cells were transfected with pcDNA/GW-N-EmGFP/ZnT-1 to produce a 
GFP fusion protein. In addition, untransfected cells or cells transfected with the 
GFP vector or pT-REx/GW/ZnT-1 were used as controls. Transfected cells will be 
referred to as GFP/ZnT-1, GFP and REx/ZnT-1 cells for AML12 cells transfected 
with  pcDNA/GW-N-EmGFP/ZnT-1,  GFP  vector  and  pT-REx/GW/ZnT-1 
respectively, and untransfected cells, simply as AML12 cells hereafter.  
 
After a 24 hour period cells in 6 and 12 well plates were approximately 80% 
confluent  and transient transfections were carried out using Lipofectamine
™ and 
PLUS
™ Reagents (Invitrogen) according to the manufacturer‟s recommendations. 
1 µg of plasmid DNA was diluted for every 100 µL of OptiMEM and after mixing 
thoroughly 7.5 µL or 3 µL of PLUS
™ reagent was added per well in 6 or 12 well 
plates, respectively. The reaction was mixed gently and left to incubate for 5 min 
at room temperature. Lipofectamine
™ LTX reagent was mixed gently and 12.5 µL 
or  5  µL  was  added  per  well  in  6  or  12  well  plates,  respectively  and  mixed 
thoroughly before a 30 min incubation at room temperature. Then, 500 µL or 200 
µL of DNA-Lipofectamine
™ LTX complex was added to each well of a 6 or 12 
well plate respectively in a drop wise fashion, and rocked gently to mix before   72 
incubating at 37°C for 6 hours after which the medium was replaced and the cells 
were incubated for a further 42 hours. 
 
2.4.12 Extraction of RNA from cells 
RNA  was  extracted  from  untransfected  AML12  cells  and  AML12  cells 
transfected  with  pcDNA/GW-N-EmGFP/ZnT-1,  GFP  vector  or  pT-
REx/GW/ZnT-1. After washing the cells with 2 mL PBS, 300 µL of cold TRI 
Reagent was added to each well, mixed immediately and left to incubate for 10 
min at RT. The cells were lysed by pipetting and then transferred to a 0.6 mL 
microcentrifuge tube and incubated for 5 min at RT. After the addition of 30 µL 
of BCP the tubes were vigorously shaken for 30 s before incubating for a further 
10 min at RT. The tubes were centrifuged (16000g; 15 min; 4°C) and the aqueous 
phase containing RNA was transferred to a 1.5 mL low adhesion microcentrifuge 
tube. An equal volume of isopropanol was added to precipitate the RNA and the 
tube was mixed by inverting. Following incubation (10 min; RT) the tube was 
centrifuged (16000g; 5 min; 4°C) to precipitate the RNA and the supernatant was 
removed. The RNA pellet was washed with 200 µL 75% ethanol, dislodged and 
centrifuged (8000g; 5 min; 4°C). The supernatant was removed and the pellet air 
dried before dissolving in 15 µL of nuclease free water (15 min; 55°C). 
 
2.4.13 Fluorescence Microscopy 
Fluorescence microscopy was undertaken to determine the cellular location of the 
ZnT-1  protein.  Three  wells  of  a  12  well  plate  containing  AML12  cells  were 
transfected with pcDNA/GW-N-EmGFP/ZnT-1 or GFP vector alone as previously 
described (Section 2.4.11) and incubated for 24 hours. GFP/ZnT-1 and GFP cells   73 
were transferred to the wells of a chamber slide. The medium was removed from 
each well of the 12 well plate and the cells were washed with 1 mL PBS before 
adding Trypsin-EDTA to remove the cells from the plate. 1 mL medium was 
added to each well and transferred to a microcentrifuge tube. After centrifugation 
(700g,  3  min)  the  supernatant  was  removed  and  a  further  1  mL  of  medium 
containing  gentamicin  (160  ng)  was  added.  After  using  a  syringe  to  remove 
clumps, 100 µL of the cell suspension was added to wells of the chamber slide 
and distributed evenly by gently rocking. The cells were incubated at 37°C for 24 
hours after which the medium was removed and the cells were washed twice with 
1 ml of cold PBS. 1 mL of ice cold acetone:methanol (1:1) was added to the wells 
to fix the cells and after incubating (4°C, 20 min) the cells were washed twice 
with 1 mL cold PBS before removing the chambers and allowing the slide to air 
dry. A cover slip was mounted using a drop of Prolong
® Gold antifade reagent 
with DAPI. 
 
The  GFP/ZnT-1  and  GFP  cells  were  visualised  on  an  Eclipse  TE2000-U 
Microscope using DAPI and GFP/Alexa Fluor 488 excitation filters of 330 – 380 
nm and 450 – 490 nm respectively and images were captured with a Nikon DS –
L1 Camera.  
 
2.4.14 Protein Extraction 
AML12, GFP/ZnT-1 and GFP cells were washed with 1 mL PBS after which a 
further 1 mL was added to each well and a cell scraper was used to remove the 
cells. Replicate wells were pooled into 1.5 mL microcentrifuge tubes, centrifuged 
(10,000g, 5 min) and the supernatant removed. 100 µL of SDS Lysis Buffer was   74 
added to each tube and the pellet was resuspended before sonication (3.2 mm 
probe; 15 s; 40V). After centrifugation (16,000g, 20 min, 4°C) the supernatant 
was transferred to clean low adhesion microcentrifuge tubes and stored at 4°C 
(short term) or -80°C (long term). 
 
2.4.15 Quantification of Protein 
Extracted  protein  was  quantified  using  the  Pierce  Bicinchoninic  Acid  (BCA) 
Protein Assay Kit (Progen) which is based on the reduction of Cu
2+ to Cu
1+ by 
protein in the presence of an alkaline medium, and the chelation of Cu
1+ by the 
BCA-containing  reagent  which  forms  a  coloured  product.  The  reaction  was 
carried out according to the manufacturer‟s instructions. Briefly, BSA (2 mg/mL) 
was  used  as  the  protein  standard  and  was  diluted  with  Triton/NaOH  to  final 
concentrations  of  0  –  500  µg/mL.  Protein  samples  were  diluted  1:39  with 
Triton/NaOH. 20 µL of each standard or sample was added to wells of a 96 well 
plate  followed  by  the  addition  of  200  µL  working  reagent  (1:50  solution 
containing  colour  reagents  B  and  A).  Following  1  hour  incubation  at  37°C, 
absorbance  was  measured  on  a  FLUOstar  Optima  Microplate  Reader  at  a 
wavelength of 570 nm. 
 
2.4.16 Western Blot Analysis of Protein 
50 µg of each protein was transferred to 0.6 mL low adhesion nuclease free tubes 
with 3.75 µL 4x sample buffer and nuclease free H2O to a final volume of 15 µL. 
The samples were heated at 95°C for 5 min to inactivate proteases and denature 
proteins and briefly centrifuged (10,000g, 10 s) to mix contents.   75 
ZnT-1 was detected using a NuPAGE
® 4-12% Bis-Tris pre-cast gel according to 
the  manufacturer‟s  instructions  (Invitrogen).  Briefly,  the  gel  was  rinsed  with 
Milli-Q  H2O  and  the  comb  removed  before  rinsing  the  sample  wells.  After 
positioning  the  gel  in  the  QuickPoint
™  Electrophoresis  Cell,  the  inner  buffer 
chamber was filled with 1x MOPS SDS Running Buffer (Invitrogen) until the 
wells were submerged. 
 
10 µL of Molecular Weight Marker (5 µL MagicMark
™ XP Western Standard; 5 
µL Novex Sharp Protein Standard) was loaded into the first well. 15 µL of each 
protein sample was loaded into the remaining wells and the outer buffer chamber 
was  filled  with  1x  MOPS  SDS  Running  Buffer.  The  samples  were 
electrophoresed at 200 V for approximately 1 hour until the dye had migrated to 
the bottom of the gel. 
 
Following electrophoresis the gels were removed from the cell. Three filter papers 
pre-soaked in transfer buffer were arranged on the cathode of a transfer block 
followed  by  the  gel,  a  nitrocellulose  blotting  membrane  (Fisher  Biotec)  pre-
soaked in transfer buffer and a further three pre-soaked filter papers (Figure 2.1). 
The anode was placed on top of the stack and the proteins were transferred onto 
the membrane for 1 hour at 280 mA. 
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           Anode (Top) 
 
      Cathode (Bottom) 
Figure 2.1: Semi-Dry Transfer Assembly Stack 
 
Upon completion, the transfer stack was disassembled and the gel stained with 
Coomassie blue dye for a minimum of 30 min and de-stained in Milli-Q H2O to 
confirm transfer of proteins. At the same time, the membrane was soaked in a 5% 
blocking solution for 30 min with agitation followed three brief rinses in PBS. 
 
2.4.16.1 Detection of ß-Actin, ZnT-1/GFP, and GFP 
Initially ß-Actin was detected by incubating the membrane with 5 mL of primary 
antibody (Section 2.2.5) overnight at 4°C with agitation after which the membrane 
was rinsed three times with PBS followed by a wash for 5 min with agitation. 
After repeating the rinse process twice, the membrane was incubated with 5 mL of 
secondary antibody (Section 2.2.5). After 1 hour incubation at room temperature 
with agitation, the membrane was rinsed three times with PBS followed by a wash 
for  5  min  with  agitation  as  described  above.  Detection  was  achieved  by 
chemiluminescence  using  the  Western  Lightning™  Plus-ECL  Detection  Kit 
(Perkin  Elmer)  according  to  the  manufacturer‟s  instructions.  Briefly,  the 
3 x Filter Paper  
3 x Filter Paper  
Gel 
Membrane   77 
membrane was positioned on a transparent sheet on the VersaDoc Imaging system 
3000 platform. After combining 2 mL each of Enhanced Luminol Reagent Plus 
and Oxidising Reagent Plus the solution was poured over the entire surface of the 
membrane and exposed for 300 s allowing a number of images to be captured. 
 
The  membrane  was  washed  three  times  in  PBS  before  carrying  out  a  second 
incubation/wash/incubation  process  with  primary  and  secondary  antibodies 
(Section 2.2.5) to detect GFP.  
 
2.4.17 Iron and Zinc Uptake/Release Assays 
Iron and zinc transport was examined by incubating GFP/ZnT-1 and GFP cells 
with radiolabelled iron or zinc. 
 
To test which form of zinc was most efficiently taken up, AML12 cells were 
incubated with either 
65ZnCl2 (1 µM) or 
65Zn citrate (1 µM). In addition, DTPA 
was  examined  for  its  effectiveness  to  chelate  zinc.  Subsequent  assays  were 
conducted  with 
65Zn  citrate  (10  µM)  or 
59Fe  citrate  (10  µM)  for  uptake 
experiments  with  the  addition  of  DTPA  or  DFO  for  zinc  or  iron  release 
experiments respectively. 
 
GFP/ZnT-1 and GFP cells were washed 3 times with warm HBSS and 0.4 mL 
59Fe citrate was added to each well. Following a 1 hour incubation at 37°C the 
cells were washed 5 times with cold HBSS and 0.4 mL of release medium (RT) 
containing  DFO  was  added  to  each  well.  Cells  were  incubated  at  37°C  for 
between 15 min and 24 hours after which the release medium was collected and   78 
the cells were washed 5 times with cold HBSS. 800 µL of Triton/NaOH was 
added to each well and incubated briefly and the cell lysates collected. The above 
procedure was repeated for zinc uptake and release. Cells were incubated in 
65Zn 
citrate followed by washing, incubation in release medium containing DTPA and 
a  final  washing  step  before  the  cells  were  lysed.  In  addition,  standards  were 
prepared with 50 µL 
59Fe citrate or 
65Zn citrate incubation solution. 
 
59Fe  or 
65Zn  were  counted  for  gamma  radiation  in  a  Wallac  Wizard  3”  1480 
gamma Counter. Specific activity was determined for 
59Fe and 
65Zn standards. 
Protein concentration was measured on the cell lysates using BCA protein assay 
previously described in Section 2.4.15 with the exception that protein samples 
were not diluted. 
 
The uptake and release of both iron and zinc, expressed as nmol metal/g protein 
were calculated from counts per minute values detected by the gamma counter, 
the specific activity of 
59Fe and 
65Zn standards (cpm/nmol) and the amount of 
protein (µg/mL). 
 
2.4.18 Statistical Analysis 
Results were analysed using Microsoft Excel and are expressed as means ± SD or 
SEM.  Initial  F-tests  were  carried  out  to  establish  the  assumption  of  equal  or 
unequal variances after which the appropriate unpaired t-tests were performed. A 
difference was statistically significant if p < 0.05. 
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Introduction 
 
mRNA levels of the two ZnT-1 isoforms as well as those of Fpn, TfR1 and Hamp 
were measured to determine gene expression. Liver tissue collected from wild 
type, iron loaded and iron deficient mice as well as Hfe knockout, TfR2(Y245X) 
mutant  and  Hfe-/-/TfR2(Y245X)  double  mutant  mouse  models  of 
haemochromatosis was analysed by RT-PCR.  
 
PCR was carried out to amplify ZnT-1 after which it was cloned using Gateway
® 
Technology vectors to create the expression clone pcDNA/GW-N-EmGFP/ZnT-1 
and control clone. In addition, fragments of ZnT-1 were cloned into the pGEM
®-T 
Easy Vector to generate standard curves for RT-PCR analysis.  
 
AML12, a mouse hepatocyte line was cultured and transfected with the ZnT-1 
expression clone or control GFP plasmid. Cells were visualised by fluorescence 
microscopy to determine ZnT-1 localization, and mRNA levels of ZnT-1, Fpn, 
Dmt1 and Zip14 were measured by RT-PCR. Furthermore, protein was extracted 
from the transfected and non-transfected cells and analysed by Western blotting. 
Additionally,  transfected  and  non-transfected  cells  were  incubated  with 
radiolabelled zinc and iron to determine cellular uptake and release of the metals. 
 
 
 
 
   81 
3.1 Generating a Standard Curve for Real-Time  PCR 
 
3.1.1 PCR of a ZnT-1 Fragment to Generate a Standard Curve 
PCR was carried out to amplify a fragment of the ZnT-1 gene to create plasmid 
standards  to  be  used  in  RT-PCR  (see  Section  2.4.6.2).  Two  sets  of  primers, 
qF2/qR2  and  qF3/qR3,  were  used  to  amplify  the  short  and  long  untranslated 
regions producing 210 bp and 234 bp products, respectively (Figure 3.1). 
         
       
         
           
 
 
Figure 3.1: Agarose Gel showing ZnT-1 fragments amplified by PCR. Lane M 
contains 1 Kb Plus Molecular Weight Marker and lane 1 and 2 contain ZnT-1 
fragments amplified from the short and long untranslated regions respectively. 
 
3.1.2 Cloning of ZnT-1 Fragments to Generate Standard Curves 
ZnT-1 fragments were cloned into pGEM-T in order to generate standard curves 
for RT-PCR. Two fragments were amplified and subsequently cloned as described 
in Sections 2.4.6.2 and 2.4.9.4 after which RT-PCR (Section 2.4.5) was used to 
verify  the  presence  of  each  insert.  The  melt  peak  shows  that  the  SUI  PCR 
products had the same melt temperature and that this was different from the melt 
temperature for the LUI PCR products (Figure 3.2). 
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Figure 3.2: Melt Curves of ZnT-1 Fragments. Melt Curve showing the different 
melt peaks generated for the SUI and LUI PCR products. 
 
3.2 Real-Time Polymerase Chain Reaction 
To analyse the role of ZnT-1 in iron transport, expression of ZnT-1 was examined 
in wild type, iron loaded, iron deficient, Hfe knockout, TfR2 mutant and double 
mutant mouse models by RT-PCR. 
 
RNA was extracted from mouse liver as previously described (Section 2.4.1) and 
DNase  treated  to  remove  any  remaining  genomic  DNA  (Section  2.4.2).  RNA 
integrity was examined by agarose gel electrophoresis to verify the presence of 
the 28S and 18S bands (Figure 3.3) 
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Figure 3.3: Representative Agarose Gel of RNA samples. RNA samples were  
electrophoresed on a 1.5% agarose gel. Lane M contains 1 Kb Plus Molecular 
Weight Marker, lanes 1- 9 contains RNA extracted from AML12 cells, lanes 10-
18 contains RNA extracted from mouse liver. 
 
 
 
Reverse  transcription  was  carried  out  on  RNA  to  generate  cDNA  after  which 
samples  were  analysed  by  RT-PCR  (Sections  2.4.4;  2.4.5).  RT-PCR  reactions 
were carried out to measure expression of genes in whole liver or a hepatocyte 
cell line. 
  
RT-PCR uses fluorophores to detect levels of gene expression which correspond 
to the number of copies of mRNA of the gene of interest that exist for a particular 
gene. During amplification the exponential phase of the reaction was monitored 
using  SYBR  green,  a  fluorescent  dye  which  binds  to  dsDNA,  and  increases 
exponentially in intensity with increasing number of cycles. A quantitation curve 
was generated which plots the fluorescence intensity versus the number of cycles 
on  a  semi-log  graph.  The  threshold,  on  the  quantitation  curve,  was  used  to 
calculate the CT values and give the line of best fit for the plasmid standard curve 
(10
1 – 10
10). The copy numbers for each sample were calculated from the plasmid 
standard curve and normalized to ß-actin. 
 
After  amplification,  products  were  subjected  to  a  melt  cycle  where  the 
temperature increased in increments of 1°C from 72°C to 99°C. This identifies the 
peak melting temperature of the PCR product and is specific to each product
79.     84 
The melt peak was analysed to verify the amplification of only a single product 
and this was confirmed by agarose gel electrophoresis and the product size was 
determined. 
 
Figure  3.4  shows  a  representative  quantitation  curve  (a),  melt  curve  (b)  and 
standard curve (c) with samples plotted in red.  
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Melt Peak 
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Figure 3.4: Representative Curves generated in RT-PCR. (a) Quantitation 
curve shows a semi-log graph of SYBR green fluorescence vs. cycle number. (b) 
Melt curve illustrates the peak which is the specific melting temperature of the 
PCR product. (c) Standard curve shows the line of best fit generated from the 
CT values for increasing copy numbers of the standard plasmid (10
3 – 10
8; in 
blue) and the samples quantified  from the standard curve (in red). 
 
 
 
Figure 3.5 is a representative gel containing PCR products from RT-PCR. 
 
 
 
 
             
 
 
 
Figure 3.5: Representative Agarose Gel of RT-PCR products. Products were 
electrophoresed  on  a  1%  agarose  gel.  Lane  M  contains  1  Kb  Plus  Molecular 
Weight Marker, lanes 1 – 4 contain PCR products from RT-PCR using ZnT-1 
qF1/qR1 primers which amplified a 228 bp product from wild type, Hfe, TfR2 
and iron loaded mouse liver tissue respectively. 
 
 
 
3.2.1 Liver mRNA Expression 
RT-PCR  reactions  were  carried  out  to  measure  expression  of  the  two  Znt-1 
isoforms, Fpn, TfR1 and Hamp in mouse liver. 
 
200 bp 
 
  M        1         2         3         4 
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ZnT-1 (SUI) 
mRNA expression of the SUI of  ZnT-1  was  significantly lower in  the double 
mutant  mice  compared  to  wild  type  mice  (Figure  3.6).  No  other  significant 
differences were observed. 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 3.6: ZnT-1 (SUI) liver mRNA expression in wild-type, Hfe Knockout, 
TfR2 mutant, iron loaded, iron deficient and double mutant mice. Results are 
expressed relative to the housekeeping gene ß-actin as mean ± SEM, n = 6-8 (α = 
0.05). *Significant differences were observed in double mutant mice compared to 
wild type mice (p < 0.05). 
 
 
 
ZnT-1 (LUI) 
In  the  LUI  of  ZnT-1,  mRNA  expression  was  significantly  higher  in  the  iron 
deficient  mice  than  in  the  wild  type  mice  (Figure  3.7).  No  other  significant 
differences were observed. 
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Figure 3.7: ZnT-1 (LUI) liver mRNA expression in wild-type, Hfe Knockout, 
TfR2 mutant, iron loaded, iron deficient and double mutant mice. Results are 
expressed relative to the housekeeping gene ß-actin as mean ± SEM, n = 6-8 (α = 
0.05). *Significant differences were observed in iron deficient mice compared to 
wild type mice (p = 0.002). 
 
 
 
Ferroportin 
A significantly higher Fpn expression was observed in Hfe knockout, TfR2 and 
iron loaded mice than in the wild type mice (Figure 3.8).  
 
 
 
 
 
 
 
 
Figure 3.8: Fpn liver mRNA expression in wild-type, Hfe Knockout, TfR2 
mutant,  iron  loaded,  iron  deficient  and  double  mutant  mice.  Results  are 
expressed relative to the housekeeping gene ß-actin as mean ± SEM, n = 6-8 (α = 
0.05). *Significant differences were observed in  Hfe knockout, TfR2, and iron 
loaded mice compared to wild type mice (p < 0.005). 
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TfR1 
TfR1  mRNA  expression  was  significantly  higher  in  iron  deficient  mice  and 
significantly lower in double mutant mice compared to wild type mice (Figure 
3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: TfR1 liver mRNA expression in wild-type, Hfe Knockout, TfR2 
mutant,  iron  loaded,  iron  deficient  and  double  mutant  mice.  Results  are 
expressed relative to the housekeeping gene ß-actin as mean ± SEM, n = 6-8 (α = 
0.05). *Significant differences were observed in iron deficient (p < < 0.0001) and 
double mutant mice compared to wild type mice (p = 0.01). 
 
 
 
Hepcidin 
mRNA expression of Hepcidin was significantly lower in Hfe, TfR2, iron deficient 
and double mutant mice than in wild type mice (Figure 3.10). In iron loaded mice, 
hepcidin expression was significantly higher than in wild type mice (Figure 3.10). 
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Figure 3.10: Hepcidin liver mRNA expression in wild-type, Hfe Knockout, 
TfR2 mutant, iron loaded, iron deficient and double mutant mice. Results are 
expressed relative to the housekeeping gene ß-actin as mean ± SEM, n = 6-8 (α = 
0.05).*Significant differences were observed in Hfe (p < 0.001), TfR2 (p < 0.001), 
iron loaded (p < 0.05), iron deficient (p < 0.0005) and double mutant mice (p < 
0.0005) compared to wild type mice. 
 
 
 
3.3 Cloning ZnT-1 
 
3.3.1 PCR of ZnT-1 Coding Sequence for Cloning 
PCR was carried out using cDNA generated from RNA extracted from wild type 
mouse liver tissue as a template and attB primers to amplify the coding sequence 
of ZnT-1 and generate a 1574 bp product (Section 2.4.6.1). Several reactions were 
required to optimise conditions before the product was successfully amplified. 
Conditions such as DNA Polymerases, Mg
2+ and primer concentrations and PCR 
enhancing  agents  such  as  PCR  enhancer  and  DMSO  as  well  as  annealing 
temperatures (TA) were required to successfully amplify the sequence.  However, 
once  the  product  was  cloned  into  Gateway
®  pDONR221  vector  and  the  entry 
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clone was constructed, subsequent sequencing revealed mutations which resulted 
in  two  amino  acid  changes  in  a  conserved  region.  Therefore,  further  PCR 
reactions were carried out using Pfx50™ DNA polymerase which has a higher 
proofreading ability (50 times improved fidelity) than Taq DNA polymerase
80. 
Figure 3.11 shows a single band consistent with the expected size of 1574 bp. 
       
 
 
   
 
 
     
        
        
 
Figure 3.11: Agarose Gel of attB-ZnT-1 PCR product amplified using Pfx50 
Polymerase. Lane M contains 1 Kb Plus Molecular Weight Marker and lane 1 
contains the purified product and lane 2 is the –ve control which contains the 
master mix without template DNA indicating that there was no contamination. 
 
 
 
In addition, another mutated clone was discovered which will be referred to as the 
short coding isoform (SCI) hereafter. The SCI was missing 269 nucleotides from 
the 5‟ end of the coding sequence which translated a 428 amino acid protein. A 
protein topology prediction in Geneious
81 revealed a five transmembrane protein 
with  an  extracellular  carboxy  terminus.  Furthermore,  the  protein  lacked  the 
histidine-rich loop common to most zinc transporters. Unfortunately, due to time 
constraints, it was not possible to investigate this „isoform‟ further. 
 
3.3.2. Construction of Expression Clones 
The construction of pcDNA/GW-N-EmGFP/ZnT-1 was achieved via a two-step 
cloning  process.  Initially,  the  entry  clone  pENTR221-ZnT-1  was  created  as 
described in 2.4.9.1 by cloning attB-ZnT-1 into the Gateway
® pDONR221 vector 
1.65 Kb 
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and  sequenced  (Section  2.4.9.2).  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-
REx/GW/ZnT-1  were  produced  as  described  in  Section  2.4.9.3  by  cloning 
pENTR221-ZnT-1 into Gateway
® pcDNA6.2/N-EmGFP-Dest and pT-REx-DEST 
destination vectors respectively.   
 
To  verify  if  bacterial  colonies  contained  pENTR221-ZnT-1,  a  preliminary 
screening process was undertaken. PCR reactions as described in Section 2.4.6 
were carried out on bacterial colonies transformed with the pENTR221-ZnT-1 
recombinant  to  determine  the  presence  and  size  of  the  product  after  which 
products were analysed by agarose gel electrophoresis. Samples in lanes 10, 13, 
14, 15, 16 and 18 appear on the gel as one fragment consistent with the expected 
size  of  1574  bp  indicating  the  colonies  contained  pENTR221-ZnT-1  (Figure 
3.12). 
 
 
 
 
 
 
 
Figure 3.12: Agarose Gel of pENTR221-ZnT-1 PCR products amplified from 
bacterial colonies. Lane M contains 1 Kb Plus Molecular Weight Marker, lanes 1 
– 9 contains PCR products amplified from bacterial colonies from the 20 µL plate 
and lanes 10-18 contains PCR products amplified from bacterial colonies from the 
100 µL plates. 
 
 
Consequently  the  six  purified  entry  clones  were  submitted  for  sequencing  to 
definitively  confirm  the  correct  gene  was  cloned  and  ensure  it  was  free  from 
mutations. After analysis as described in Section 2.4.9.2, three entry clones, from 
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colonies 13, 14 and 16 were confirmed as being mutation free ZnT-1. Figure 3.13 
is a representation of the protein alignment of the three clones sequenced. 
 
 
Figure  3.13:  A  representative  amino  acid  sequence  alignment.  The  image 
shows the amino acid sequence alignment for the plasmid derived from colony 13 
and  is  representative  of  the  three  correct  clones.  The  NCBI  NP_033605.1
82 
sequence is highlighted. 
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After sequencing revealed three pENTR221-ZnT-1 clones contained the ZnT-1 
transcript,  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1  were 
constructed and screened by both PCR and RT-PCR (Section 2.4.5; 2.4.6). Figure 
3.14 shows that PCR products amplified from bacterial colonies transformed with 
the pcDNA/GW-N-EmGFP/ZnT-1 and pT-REx/GW/ZnT-1 recombinants were of 
the  expected  size    of  1574  bp  and  analysis  of  the  melt  curve  revealed  the 
pcDNA/GW-N-EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1  PCR  products  had  the 
same melt temperature. 
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Figure 3.14 Agarose Gel and Melt Peak. (a) Agarose gel of pcDNA/GW-N-
EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1  PCR  products  amplified  from 
bacterial colonies. Lane M contains 1 Kb Plus Molecular Weight Marker, lanes 1 
– 3 contain pcDNA/GW-N-EmGFP/ZnT-1, lanes 4 – 6 contain pT-REx/GW/ZnT-
1, lane 7 contains  the pENTR221-ZnT-1 clone from colony 14 as a +ve control 
and lane 8 contains the –ve control confirming there was no contamination. (b) 
Melt Peak derived from RT-PCR of pcDNA/GW-N-EmGFP/ZnT-1 & pT-
REx/GW/ZnT-1 amplification. The melt curve showing all of the PCR products 
have the same melt temperature. 
1.65 Kb   
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Therefore  the  expression  clones  were  transformed  (Section  2.4.9.3)  using  one 
pcDNA/GW-N-EmGFP/ZnT-1 clone and one pT-REx/GW/ZnT-1 clone, and after 
growing up in LB broth, an additional RT-PCR was carried out and the resulting 
melt curve for each clone showed the melt temperature was the same (Figure 
3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.15:  Melt  Curve  derived  from  RT-PCR  of  pcDNA/GW-N-
EmGFP/ZnT-1 and pT-REx/GW/ZnT-1 starter culture. The melt curve shows 
a similar curve for pcDNA/GW-N-EmGFP/ZnT-1 and pT-REx/GW/ZnT-1. 
 
 
 
3.4 Fluorescence Microscopy 
Fluorescence microscopy was undertaken to determine the cellular location of the 
ZnT-1  protein  (Section  2.4.13).  GFP/ZnT-1  and  GFP  cells  were  fixed  to  a 
microscope  slide  and  stained  with  Prolong
®  Gold  antifade  reagent  containing 
DAPI. In GFP/ZnT-1 cells, green fluorescence (as indicated) was observed on the 
cell membrane (Figure 3.16a). In contrast, green fluorescence was observed on the 
cell  membrane  and  intracellularly  in  GFP  cells  (Figure  3.16b).  DAPI  staining 
illustrated the nuclei (Figure 3.16c and d) and merging of the images illustrates 
expression of ZnT-1 on the cell membrane (Figure 3.16e and f). Furthermore, 
figure 3.16e shows some intracellular punctate staining. 
pcDNA/GW-N-EmGFP/ZnT-1 
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Figure  3.16:  Fluorescent  Images  of  AML12  Cells  transfected  with  the 
GFP/ZnT-1  construct  or  GFP  alone.  (a)  GFP/ZnT-1  cells  show  green 
fluorescence  on  the  cell  membrane  as  marked.  (b)  GFP  cells  show  green 
fluorescence throughout the cell. (c) DAPI staining of GFP/ZnT-1 cells and (d) 
GFP  cells  illustrates  the  nuclei.  (e)  In  GFP/ZnT-1  cells,  the  cells  display 
intracellular punctate staining and expression is seen on the cell membrane as 
marked. (f) In GFP cells expression is shown throughout the cell. 
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         81 kDa (GFP/ZnT-1) 
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3.5 Western Immunoblotting to detect the GFP protein 
Total protein was extracted from AML12, GFP/ZnT-1 cells and GFP cells and 
quantitated (Section 2.4.14 and 2.4.15). GFP/ZnT-1 and GFP protein expression 
in AML12 cells was analysed by Western Blot as described in Section 2.4.16. 
GFP/ZnT-1  and  GFP  protein  in  AML12  cells  was  detected  by  using  rabbit 
polyclonal  GFP  primary  antibody  and  goat  anti-Rabbit  IgG  horseradish 
peroxidase conjugate secondary antibody (Figure 3.17).  
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Figure 3.17: ZnT-1 Protein Expression. ZnT-1 protein levels were measured by 
Western  Blotting  by  detecting  the  GFP  in  transfected  AML12  cells.  Bands 
specific for GFP/ZnT-1 are seen in lanes 3 and 6, GFP are in lanes 2 and 5 and ß-
actin in lanes 1 – 6. 
 
 
 
3.6 Iron and Zinc Uptake and Release Assays 
To test which form of zinc was most efficiently taken up, AML12 cells were 
incubated with either 
65ZnCl2 or 
65Zn citrate. Furthermore, it was important to 
establish whether DTPA would be an effective zinc chelator to ensure that once 
released from the cell, zinc would not be taken up again (Section 2.4.17). Figure 
3.18 shows that both 
65ZnCl2 and 
65Zn citrate were equally effective at donating 
zinc to the cells. In addition, the results show that when DTPA was added to the 
medium, uptake was significantly reduced thus it was concluded that DPTA is an   97 
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effective zinc chelator (Figure 3.18). Citrate and DFO are known to be efficient 
for uptake and release of iron respectively
83, and the use of these in iron assays is 
standard  procedure  in  this  laboratory.  Therefore,  to  minimise  the  differences 
between assays, subsequent assays were performed with 
65Zn citrate or 
59Fe citrate 
for uptake and DTPA or DFO for release medium, for zinc and iron respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Uptake of 
65ZnCl2, 
65Zn Citrate, 
65Zn Citrate DTPA and 
65ZnCl2 
DTPA in AML12 cells. Cells were incubated with 
65ZnCl2, 
65Zn Citrate, 
65Zn 
Citrate or 
65ZnCl2 DTPA (1µM Zn; 160nM Citrate; 100 µM DTPA) for 1 h at 
37°C.  Results  are  expressed  as  mean  ﾱ  SE,  n  =  3  (α  =  0.05).  *Significant 
differences  were  observed  in  Zn  Citrate  DTPA  and  ZnCl2  DTPA  uptake 
compared to both 
65ZnCl2 and 
65Zn Citrate (p << 0.001). 
 
 
 
An efflux time course study was conducted to establish the optimum release time. 
Untransfected AML12 cells pre-incubated with 
65Zn Citrate or 
59Fe Citrate (37°C, 
1 h) were washed and re-incubated in release medium containing DTPA (100 µM) 
or DFO (100 µM) for 15, 60, 120 and 240 min after which the release medium 
was collected and the amount of 
59Fe and 
65Zn was measured (Section 2.4.17). 
Iron and zinc released from the cell increased over the 240 min period. (Figure 
3.19)  Iron released in the first 60 min accounted for almost 90% of the total iron 
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released. There was a minimal amount of efflux over the next 180 min and at T240 
about 85% of iron remained in the cell. A similar trend was observed for zinc 
where 75% of the total zinc released occurred in the first 60 min. Between T60 and 
T120, the amount released was negligible; however, there was a significant amount 
of zinc released in the final 120 min and by T240 there was 70% of zinc remaining 
in the cell (Figure 3.19). More zinc than iron was released from the cell. 
   
     
 
 
 
 
 
 
 
 
Figure 3.19:  % Total of Iron (■) or Zinc (□) Efflux from AML12 cells over 
240 minutes. Results are expressed as the amount of zinc or iron released as a 
percentage of total cellular uptake. Mean ﾱ SE, n = 3 (α = 0.05). *A significant 
amount of iron and zinc was released from the cell between T15 and T60 (p = 
0.003). The amount of iron released from the cell from T60 to T240 was negligible 
as  was  the amount of zinc released from  T60 to T120. There was  a significant 
amount of zinc released from T120 to T240 (p = 0.01). 
 
 
 
Subsequent tests were carried out on GFP and GFP/ZnT-1 cells as described in 
Section 2.4.17. Iron and zinc efflux was measured at 15 min, 30 min, 60 min and 
120 min. There was no significant difference in iron efflux between the GFP and 
GFP/ZnT-1 cells (Figure 3.20a). In contrast zinc efflux was significant between 
GFP and GFP/ZnT-1 at 60 min (Figure 3.20b). 
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Figure  3.20:  %  Total  of  Iron  (a)  and  Zinc  (b)  efflux  from  GFP  (□)  and 
GFP/ZnT-1 (■) cells over 120 minutes. Results are expressed as the amount of 
zinc or iron released as a percentage of total cellular uptake. Mean ± SE, n = 3 (α 
= 0.05). * There was a significant difference in the amount of zinc efflux between 
GFP  and  GFP/ZnT-1  cells  at  60  minutes  (p  <  0.05).  There  were  no  other 
differences  observed  in  the  amount  of  zinc  or  iron  efflux  between  GFP  and 
GFP/ZnT-1 cells. 
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Figure 3.21 shows the internalised fraction of iron and zinc in GFP and GFP/ZnT-
1 cells. There was no significant difference observed in internalised iron between 
GFP and GFP/ZnT-1 cells (Figure 3.21a). However, at 30 minutes there was 
significantly more zinc internalised in the GFP/ZnT-1 cells compared to the GFP 
cells (Figure 3.21b). No other notable differences were observed. 
 
(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure  3.21:  nmol  of  Iron  (a)  and  Zinc  (b)  internalised  in  GFP  (□)  and 
GFP/ZnT-1 (■) cells. Results are expressed as mean ﾱ SE, n = 3 (α = 0.05). * 
There was a significant difference in the amount of internalised zinc for GFP and 
GFP/ZnT-1  cells  at  30  minutes  (p  <  0.05).  There  were  no  other  differences 
observed in the amount of internalised iron or zinc in GFP and GFP/ZnT-1 cells. 
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3.7 mRNA Expression of Genes in AML12 Cells 
RT-PCR was performed on transfected and non-transfected AML12 cells (Section 
2.4.5).  ZnT-1  expression  was  compared  with  the  iron  transporters,  Dmt1  and 
Zip14, and the iron exporter Fpn to determine whether over-expressing ZnT-1 had 
any effect on other transporters. 
 
ZnT-1 (LCI) 
ZnT-1 expression was significantly higher in GFP/ZnT-1 and REx/ZnT-1 cells 
compared to AML12 control cells (Figure 3.22). Expression in GFP-alone cells 
was no different from control cells. ZnT-1 expression was increased in REx/ZnT-1 
cells  compared  with  AML12  and  GFP  alone  cells,  however,  ZnT-1  mRNA 
expression  was  significantly  higher  in  GFP/ZnT-1  than  in  REx/ZnT-1  (Figure 
3.22). 
 
 
 
 
 
 
 
 
 
Figure  3.22:  ZnT-1  mRNA  expression  in  AML12,  GFP,  GFP/ZnT-1  and 
REx/ZnT-1cells.  Results  are  expressed  as  mean  ±  SE,  n  =  3-6  (α  =  0.05). 
*Significant differences were observed in GFP/ZnT (p = 0.00006) and REx/ZnT-1 
cells (p = 0.003). 
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There was no significant difference of Fpn, Dmt1 and Zip14 expression between 
AML12 and GFP, GFP/ZnT-1 and REx/ZnT-1 cells (Figure 3.23; Figure 3.24; 
Figure 3.25). 
 
 
 
 
 
 
 
 
 
Figure 3.23: Ferroportin mRNA expression in AML12, GFP, GFP/ZnT-1 and 
REx-ZnT-1 cells. Results are expressed as mean ± SEM, n = 3-6 (α = 0.05). 
There were no significant differences observed (p > 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.24:  Dmt1  mRNA  expression  in  AML12,  GFP,  GFP/ZnT-1  and 
REx/ZnT-1 cells. Results are expressed as mean ± SEM, n = 3-6 (α = 0.05). 
There were no significant differences observed (p > 0.05). 
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Figure  3.25:  Zip14  mRNA  expression  in  AML12,  GFP,  GFP/ZnT-1  and 
REx/ZnT-1 cells. Results are expressed as mean ± SEM, n = 3-6 (α = 0.05). 
There were no significant differences observed (p > 0.05). 
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Introduction 
Hereditary  haemochromatosis  is  an  autosomal  recessive  disorder  of  iron 
metabolism,  characterised  by  increased  iron  absorption  and  progressive  iron 
accumulation particularly in the liver
19. It has been shown that hepatocytes can 
acquire iron in two forms; transferrin-bound iron (TBI) and non-transferrin-bound 
iron  (NTBI)
1.  Known  transporters  of  NTBI  into  the  cell  include  DMT1
84  and 
ZIP14
32,  and  FPN  is  the  only  transporter  known  to  export  iron  and  evidence 
suggests that the iron is in the form of ferrous iron
31. 
 
This study involved the characterisation of ZnT-1, to determine whether ZNT-1 is 
involved in the export of iron. mRNA expression was analysed in mouse liver and 
cells over-expressing ZnT-1. Iron and zinc release was measured in cells over-
expressing the ZnT-1 protein. 
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4.1 Liver mRNA expression 
The liver is the main site of iron storage therefore, to analyse the role of ZnT-1 in 
iron transport, SUI and LUI mRNA expression in mouse liver was examined and 
compared with the iron metabolism genes Fpn, TfR1 and Hamp. 
 
Decreased ZnT-1 (SUI), TfR1 and Hamp expression was observed in the double 
mutant    mice  (Figure  3.6;  3.9;  3.10).  In  iron  deficient  livers,  there  was  an 
increased expression of ZnT-1 (LUI) and TfR1 (Figure 3.7; 3.9) and a decrease in 
Hamp expression (Figure 3.10). Hfe -/-, TfR2 mutant and iron loaded mouse livers 
showed  an  increase  in  Fpn  expression  (Figure  3.8).  Hamp  expression  was 
decreased in Hfe and TfR2 mice, there was an increased level of expression in iron 
loaded mouse models (Figure 3.10). 
 
ZnT-1  expression  in  wild-type,  iron-loaded  and  TfR2  mice  followed  a  similar 
trend to previous microarray expression studies. In that unpublished study ZnT-1 
SUI expression was marginally lower in iron-loaded and TfR2 mice compared to 
wild-type, and ZnT-1 LUI expression remained unchanged
64. 
 
ZnT-1 is  located on the cell membrane and is  thought  to  be involved in  zinc 
efflux
57;  58,  and  Ohana  et  al.  found  a  reduction  of  ZnT-1  expression  in  cells 
expressing ZnT-1 siRNA
85. Therefore, if ZnT-1 was involved in iron transport, an 
increase in mRNA expression in iron-loaded liver should have been observed. 
However, McMahon and Cousins reported an interesting trend in their studies; in 
response to an acute oral zinc dose, an 8-fold up-regulation of intestinal ZnT-1 
mRNA  was  observed  without  a  corresponding  increase  in  ZnT-1  protein.   107 
Conversely, liver ZnT-1 protein increased 5-fold without an increase in liver ZnT-
1 mRNA expression suggesting additional factors are involved in ZnT-1 protein 
regulation
60. Furthermore, changes in ZnT-1 expression appear to parallel those of 
metallothionein 1 (MT-1) which is mediated by MTF-1, suggesting that MTF-1 
may also coordinate ZnT-1 regulation
62.  
 
On  that  basis,  it  is  reasonable  to  propose  that  ZnT-1  is  subject  to  underlying 
posttranscriptional or posttranslational regulatory factors; however, due to time 
constraints it was not possible to investigate this further. 
 
The increase in  mRNA levels  of  TfR1  in  iron deficient mice was  due to  IRP 
binding to the IRE in the TfR1 mRNA which prevents mRNA degradation
86.  
 
The increased Fpn expression seen in HFE, TfR2 and iron-loaded livers has been 
reported  previously.  The  function  of  ferroportin  is  to  export  iron  from 
hepatocytes, hence its  expression was  up-regulated in  iron loaded cells and is 
consistent  with  previous  studies  which  reported  an  increase  in  Fpn  mRNA  in 
HFE, TfR2 and iron-loaded mice repectively
71; 87; 88. Ferroportin is regulated in a 
posttranslational manner by hepcidin. Hepcidin binds to ferroportin and induces 
its  internalisation  and  degradation  thus  preventing  iron  efflux
37.  Hepcidin  is 
regulated by iron status and is secreted from the liver when iron concentration is 
high to prevent its efflux by ferroportin
89.  
 
The  decreased  Hamp  expression  observed  in  HFE,  TfR2,  iron-deficient  and 
double mutant livers and increased mRNA levels observed in iron-loaded livers is   108 
consistent with previous studies
89; 90; 91; 92; 93. Hepcidin is the key regulator of iron 
metabolism; in the hepatocyte hepcidin is stimulated with increased iron
89 and 
down regulated in anemia
90. In addition, down-regulation of Hamp expression has 
been reported in HFE
91 and TfR2 mutant mouse models
92; 93. Given that Hamp 
expression was down-regulated in both HFE and TfR2 livers, the decreased Hamp 
expression seen in the double mutant livers is to be expected. 
 
4.2 Cloning ZnT-1 to produce a GFP fusion protein 
Amplifying the ZnT-1 gene proved to be the most challenging aspect of this study 
and several PCR reactions were required before a single product of the expected 
size was obtained. The most troublesome factors were the GC-rich sequences at 
the 5‟ end of the gene and the comparatively GC-poor 3‟ region as well as the 
high  primer  melting  temperatures  (TM).  GC-rich  regions  generate  complex 
secondary structures which prevent denaturation, annealing and extension during 
PCR
75  similarly,  primers  with  high  TMs  are  susceptible  to  forming  secondary 
structures
94. 
 
The problem was overcome by using a PCR enhancer and DMSO. PCR enhancers  
facilitate amplification of problematic templates by increasing primer specificity 
and  allow  a  wider  annealing  temperature  (TA)  range
95.  DMSO  reduces  both 
template and primer TMs and relax GC secondary structures
75. Other factors that 
required  optimisation  were  MgCl2  concentration  and  TA.  The  first  successful 
amplification contained point mutations and since the product was required for 
functional  studies  further  PCR  reactions  were  performed  using  Pfx50  DNA 
polymerase which has a fifty times improved fidelity compared with Taq DNA   109 
polymerase
80.  Furthermore,  a  second  mutated  clone  was  obtained  and  the 
relevance of this will be discussed later. 
 
A single product of the correct size was amplified (Figure 3.11) and successfully 
cloned  to  produce  pcDNA/GW-N-EmGFP/ZnT-1  and  pT-REx/GW/ZnT-1. 
Sequencing results (Figure 3.13) confirmed the ZnT-1 gene was cloned and the 
sequence  was  free  from  mutations.  Transfection  of  AML12  cells  with 
pcDNA/GW-N-EmGFP/ZnT-1, pT-REx/GW/ZnT-1 or GFP alone enabled ZnT-1 
localisation, qualitative and quantitative analysis as well as functional assays to be 
performed. AML12 cells transfected with GFP alone controlled for localization of 
ZnT-1 and REx/ZnT-1 cells were to control for the presence of the GFP tag to 
validate that functional differences were as a result of ZnT-1 expression alone. 
 
The immunoblotting results confirmed the presence of the GFP/ZnT-1 and GFP 
proteins which were observed at about 80 kDa and 27 kDa, respectively (Figure 
3.17). The molecular weight of ZnT-1 protein is 54.5 kDa
96 and the GFP protein 
is 26.9 kDa
97 therefore, it is to be expected that GFP/ZnT-1 would be observed as 
80 kDa. Visualisation of GFP/ZnT-1 cells by fluorescent microscopy is consistent 
with ZnT-1 being located on the membrane as reported by Palmiter and Findley
57, 
in contrast to the control cells which showed GFP expression throughout the cell. 
Furthermore, the punctate staining observed suggests a vesicular localization of 
the fusion protein (Figure 3.16). 
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4.3 mRNA Expression of Genes in AML12 cells 
It has now been established that DMT1 and ZIP14 are capable of transporting 
NTBI into cells
32; 84 and FPN is the only transporter known to export iron
31. ZnT-1 
expression  was  analysed  in  untransfected  cells  and  cells  transfected  with 
GFP/ZnT-1,  GFP  alone  or  REx/ZnT-1  to  confirm  that  cells  containing  the 
pcDNA/GW-N-EmGFP/ZnT-1  construct  were  over-expressing  ZnT-1  and  that 
neither the GFP tag or the plasmid was responsible for functional differences. In 
addition ZnT-1 expression was compared with the iron transporters, Dmt1 and 
Zip14, and the iron exporter Fpn to determine whether over-expressing ZnT-1 had 
any affect on other transporters. 
 
In cells over-expressing ZnT-1 there was significantly higher mRNA levels of 
ZnT-1 than in AML12 cells, GFP cells and REx/ZnT-1 cells. In addition, ZnT-1 
mRNA was  significantly  higher in  REx/ZnT-1 compared to  AML12 cells  and 
GFP cells (Figure 3.22). There was no difference in expression of Fpn, Dmt1 and 
Zip14  for  GFP,  GFP/ZnT-1  or  REx/ZnT-1  compared  to  AML12  cells  (Figure 
3.23; 3.24; 3.25). 
 
In GFP/ZnT-1 cells, the significantly higher ZnT-1 expression demonstrated that 
these cells were over-expressing ZnT-1 and although REx/ZnT-1 cells were also 
significantly expressed compared to AML12 cells and cells containing GFP alone, 
Znt-1 expression in GFP/ZnT-1 was significantly higher compared to REx/ZnT-1 
cells. 
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If ZnT-1 was involved in iron transport the expression pattern would either mirror 
that of other transporters, or if its role is to regulate iron influx, as Segal et al. 
suggest occurs with zinc
59, an inverse pattern would be observed. When compared 
with Fpn, Dmt1 and Zip14 expression profiles, there did not appear to be any 
correlation which might be the reflection of an independent system at work. It is 
also possible that posttranscriptional regulation inhibited mRNA expression and 
although this is entirely speculative, Fpn, Dmt1 and Zip14 have all been shown to 
be subject to such regulatio
24; 98. 
 
4.4 Iron Uptake and Release 
Iron  transport  was  examined  by  incubating  GFP/ZnT-1  and  GFP  cells  with 
radiolabelled iron to determine whether ZnT-1 is involved in iron transport. In 
addition, zinc transport was analysed to validate the efficiency of the assay. 
 
Initial assays were to test whether 
65ZnCl2 or 
65Zn citrate was most efficient for 
uptake and establish the efficiency of DTPA as a zinc chelator showed that both 
65ZnCl2 and 
65Zn citrate were equally effective at donating zinc to the cells and 
that  DTPA  significantly  reduced  uptake  (Figure  3.18).  Citrate  and  DFO  are 
known to be efficient for uptake and release of iron respectively
83, and the use of 
these in  iron assays  is  standard procedure in  this  laboratory. Therefore assays 
were conducted with 
59Fe citrate or 
65Zn citrate for uptake and DFO or DTPA for 
release  of  iron  and  zinc  respectively.  In  addition,  a  time  course  release  study 
established that 90% of the total iron released occurred in the first 60 min and zinc 
efflux was still occurring at 4 hours (Figure 3.19). Given that the focus of this 
study was iron transport it was not necessary to test beyond that time point.   112 
Iron and zinc efflux was measured at 15 min, 30 min, 60 min and 120 min in 
GFP/ZnT-1 and GFP cells. There was no difference in GFP/ZnT-1 iron efflux 
compared to GFP cells and for zinc efflux the only significant difference observed 
was at 60 minutes (Figure 3.20). Similarly, with iron and zinc internalization, the 
only significant difference observed between GFP/ZnT-1 and GFP cells was in 
zinc  at  60 minutes, 130.57 nmol Zn per g protein  (+/- 3.65 SE) compared to 
118.06 nmol Zn per g protein (+/- 2.15 SE). 
  
Unfortunately, these results remain inconclusive as there was very little difference 
observed between GFP/ZnT-1 and GFP in zinc uptake and  release. ZnT-1 has 
been reported to be involved in zinc transport by a number of groups
57; 59; 60; 85; 99 
and in contrast to the results observed in this study. Given that zinc uptake and 
release were measured to validate the assay suggests that the iron uptake and 
release results are questionable. 
 
However, a number of factors could account for this inconsistency. Segal et al.
59  
reported no difference in zinc efflux in cells over-expressing ZnT-1 compared to 
control cells, however in cells co-expressing the L-type calcium channel (LTCC), 
a major route for zinc influx, and ZnT-1, they observed a 3-fold reduction in zinc 
influx suggesting that ZnT-1 regulates influx. In addition, Western blot analysis 
conducted by McMahon and Cousins
60 found intestinal and liver ZnT-1 protein 
migrated as a 42 and a 36 kDa protein respectively, suggesting post-translational 
modifications might regulate the steady-state level of ZnT-1 protein. Moreover, 
given the toxicity of zinc it is reasonable to propose that when subjected to zinc 
loading,  zinc  transporters  within  the  cell,  compartmentalized  the  zinc  as  a   113 
detoxification  measure  which  is  consistent  with  Palmiter  et  al.  who  reported 
prolonged  exposure  of  cells  expressing  ZnT-2  led  to  accumulation  of  zinc  in 
vesicles
51.  Furthermore,  Gaither  and  Eide  hypothesised  the  binding  of  zinc  to 
metallothionein proteins serve as a detoxification mechanism
46. 
 
4.5 Is there a mutation in ZnT-1 that produces an aberrant protein? 
The SCI was discovered whilst attempting to amplify the ZnT-1 coding sequence. 
It was missing 269 nucleotides from its 5‟ end which translated a 428 amino acid 
protein. A protein topology prediction revealed a 5 transmembrane protein with an 
extracellular carboxy terminus which is contrary to the typical ZnT structure
56. 
Furthermore,  the  protein  lacked  the  histidine-rich  loop  common  to  most  zinc 
transporters and is thought to act as a metal binding domain
56. In addition Gaither 
and  Eide  reported  alterations  within  the  loop  affected  its  metal  specificity 
suggesting  it  is  involved  in  metal  recognition
46.  Unfortunately,  due  to  time 
constraints  it  was  not  possible  to  investigate  this  isoform  further,  however, 
investigation would be desirable to determine if such an isoform exists and what, 
if any role it may have in metal transport.  
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4.6 Future Directions 
Due to time constrains there were a number of questions that remain unanswered 
and require further investigation to establish whether ZnT-1 is involved in iron 
transport. 
 
Almost certainly one of the most important issues that need to be established is 
whether  the  mutated  sequence,  namely  the  SCI  of  ZnT-1  is  involved  in  iron 
transport. 
 
In addition, performing a knockdown and repeating these experiments would be 
useful  to  determine  whether  ZnT-1  is  involved  in  iron  or  zinc  transport.   
Additionally, it has been speculated that Znt-1 is not involved in zinc efflux, but 
rather regulates its influx. Therefore, establishing whether ZnT-1 is involved in 
iron homeostasis by regulating its influx would be valuable. 
 
Moreover,  to  confirm  whether  the  Fpn,  Dmt1  and  Zip14  mRNA  expression 
observed in transfected and untransfected cells was due to mRNA degradation, a 
time-course study for transfection time could be performed. 
 
Finally, it would be useful to determine whether ZnT-1 has a hepcidin binding site 
and is therefore regulated in the same way as ferroportin. 
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4.7 Conclusion 
The liver is the main target of iron deposition, therefore it is reasonable to assume 
that if ZnT-1 was involved in iron efflux, it would be highly expressed in the liver 
in  response  to  iron-loading.  However,  it  is  equally  logical  to  suggest  that  a 
decrease in ZnT-1 expression would result in hepatic iron loading characteristic of 
haemochromatosis. In the present study, the results do not support this hypothesis.  
Furthermore, cells over-expressing ZnT-1, should have released more iron than 
control cells. Together these results imply that ZnT-1 is not an iron exporter, in 
fact, it is even reasonable to question whether it is involved in zinc export. In 
addition, this study was able to replicate a number of previous studies and as such 
it can be assumed that the results are reliable. 
 
However,  a  number  of  questions  remain  unanswered  and  therefore  it  is  not 
reasonable to definitively state that ZnT-1 is not an iron exporter. Therefore it is 
still within the realm of reason that like DMT-1 and ZIP14, it could possibly 
transport more than one metal. 
 
To  date  numerous  studies  have  been  undertaken  in  an  effort  to  elucidate  the 
location, function and regulation of zinc transporters as well as their possible role 
in disease diagnostics, and although a lot has been revealed there is still much to 
be uncovered. Whether or not that includes the role of ZnT-1 in iron transport 
remains to be seen.   
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